Page: 1
Protocol  Number: CA209908
IND Number: 119,590
EUDRACT Number 2016-004441-82
Date 12-Dec- 2016
Revised Date: 11-Sep-2017
Clinical Protocol CA209908
Phase Ib /II Clinical Trial o f Nivo lumab Monotherapy  and Nivo lumab in Combinat ion with 
Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies 
CheckMate908: CHECKpo int pathway  and nivo luMAb clinical Trial Evaluat ion 908
Revised Protoc ol 01
Medical Monitor
Lewis Strauss, MD
This document is the confidential and proprietary information of Bristol -Myers Squibb 
Company and its global affiliates (BMS). By reviewing thisdocument, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whether your 
organization will participate in and/or the performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made onl y on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, copying, 
disclosure or dissemination of this information is strictly prohibited unless expressly 
authorized in writing by BMS. Any supplemental information ( e.g., amendments) that may 
be added to this document is also confidential and proprietary to BMS and must be kept in 
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Revised Protocol No.: 01
Date: 11-Sep-2017 2confidence in the same manner as the contents of this document. Any person who receives 
this document without due authorization from BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply 
to partners to which BMS has transferred obligations, e.g., a Contract Research 
Organization (CRO).
Replace all previous version(s) of the protocol with this revised protocol and please provide a copy 
of this revised protocol  to all study  personnel under your supervisio n, and archive the previous 
versio ns.
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Revised Protocol No.: 01
Date: 11-Sep-2017 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Revised Protocol 01 11-Sep -2017To clarify protocol text based on local reviews and 
investigator feedback. 
Original Protocol 12-Dec -2016 Not Applicable
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
OVERALL RATIONALE FO R THE REVISED PROTOCOL 01
The purpose of thi s amendment i s to clari fy protocol  text based on l ocal reviews and invest igator 
feedback.
These changes affect all part icipants and should be implemented after IRB approval. 
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 01
Section & Title Description of Change
Secti on 1, Synopsis, Study  
Popul ation; Section 6.1, 
Inclusio n Cri teria, Cri terion 
2.a; Section 5.1.1, Overall 
DesignAdded that patients must 
have received Standard of 
Care therapy  and that no 
potenti ally-curative therapy  is 
available.
Secti on 1, Synopsis, Study  
Popul ation; Section 6.1, 
Inclusio n Cri teria, Cri terion 
2.a.Indicated for Cohort 1 “but 
no chemotherapy” and 
changed “thalamic” to 
“midline”; for Cohort 2, 
changed “supratentorial” to 
“non -brainstem”; for Cohort 
3, added “and chemotherapy 
(regardless of age)”; for 
Cohort 4, added “(regardless 
of age)
Secti on 2, Schedule of 
Activities, Table 2. -1, 
Screening Procedural Outline Removed pregnancy test at 
screening because a 
pregnancy test prior to the 
first dose is al ready requi red. 
Secti on 2, Schedule of 
Activities, Table 2. -1, 
Screening Procedural 
Outline; Table 2. -2, 
Nivo lumab Monotherapy  
[Modul e A] Procedural 
Outline (CA209908); Table 
2.-3, Nivo lumab + 
Ipilimumab co mbinat ion 
[Modul e B] Procedural  
Outline (CA209908); Table 
2.-4, Follow -up Procedural 
Outline (CA209908);  Guidance on whether Spine 
MRI and CSF cy topathol ogy 
are expected at baseline or 
on-study .
Revised Protocol No.: 01
Date: 11-Sep-2017 4
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 01
Section & Title Description of Change
Secti on 2, Schedule of 
Activities, Table 2. -2, 
Nivo lumab Monotherapy  
[Modul e A] Procedural 
Outline (CA209908); Table 
2.-3, Nivo lumab + 
Ipilimumab co mbinat ion 
[Modul e B] Procedural  
Outline (CA209908); Table 
2.-4, Follow -up Procedural 
Outline (CA209908Increased interval o f MRI 
scans fro m Q8 week to Q12 
week after 1 y ear on study .
Secti on 3.1.2, Checkpo int 
Inhibitors for CNS Tumors; 
Secti on 3.1.3, Checkpo int 
Inhibitors in Pediatric 
Parti cipantsUpdated informat ion on trials
of nivo lumab or ni volumab 
plus ipilimumab in adult s 
with GBM and in children 
with non-CNS tum ors
Secti on 3.2.1, Indi cations to 
be StudiedIncluded rationale for 
eligibilit y of Cohort 1 after 
initial RT rath er than at 
progression
Secti on 3.2.4, Nivo lumab 
Combined wit h IpilimumabUpdated to focus text 
specifically on CNS tumors
Synopsis, Overall Design; 
Secti on 5.1, Overall Design; 
Secti on 10.1 Sam ple Size 
Determinat ion Indicated that t arget number 
of parti cipants i s 
approximate, subject to 
recommendat ion of Study  
Steering Committee
Revised Protocol No.: 01
Date: 11-Sep-2017 5
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 01
Section & Title Description of Change
Secti on 5.1.2, Safet y Lead InIndicated that SSC may 
recommend to proceed with
Expansio n phase if 0 DLT is 
observed in the first 5 (of 6) 
in Cohort 1 or the first 7 (of 
10) parti cipants in Cohort 2 
Secti on 5.1.3, Definit ion of 
Dose -limit ing Toxi city Clarified definit ion of “DLT -
evaluable” to include subjects 
who del ay or discont inue 
treatm ent due to rel ated AE.
Secti on 5.1.5, Follow -up 
Phase; Section 5.3, End of 
Study  Definit ionAdded a sentence regarding 
the length of fo llow-up.
Secti on 5.1.6.1, Data 
Moni toring Committee; 
Secti on 5.1.6.2 ,Study  
Steering CommitteeIndicated that any  major 
recommendat ion of one 
committee would be 
communicated to the other
Secti on 5.1.6.2, Study  
Steering CommitteeAdded a condit ion that 
accrual may  be kept open to 
study  a sub -populati on
Secti on 5.5.1, Nivo lumabExpanded the just ificat ion for 
dose of nivo lumab
Secti on 6.1, Incl usion 
Criteria, Cri terion 2.f .Criterion has been m odified 
minimum intervals fro m last 
prior therapy  and added 
cauti ons f or selected pri or 
therapy  and m oved to
criterion 2.j
Revised Protocol No.: 01
Date: 11-Sep-2017 6
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 01
Section & Title Description of Change
Table 6.2 -1Added maximum permitted 
creatinine values in SI 
(umol/L) uni ts
Secti on 6.2, Exclusio n 
Criteria, cri terion 4.e; Sect ion 
7.4.1, Dose Delay Criteria; 
Secti on 8.1.1, 
Discontinuati on of  
Nivo lumab due to Toxicit y 
[Modul e A or B]; Secti on 
9.2.7, Potential Drug Induced 
Liver Injury (DILI)Defined “fixed” ULN for 
AST and ALT.
Secti on 8.1.1, 
Discontinuati on of  
Nivo lumab Due to Toxicit y 
[Modul e Aor B]Grade 3 Neurologic toxicit y 
has been added as a 
discontinuat ion criteria.
Secti on 8.1.2, 
Discontinuati on of  
Combinat ion treat ment due to 
Toxicit y [Modul e B]Added a criterion regarding 
select Grade 2 drug-related 
events; Restart of nivo lumab 
after ipilim umab 
discontinuat ion for AE m ay 
be permitted
Secti on 9.1, Efficacy 
AssessmentsAdded addit ional guidance 
for invest igators regarding 
imaging, including reference 
to RAPNO proposal. 
Clarified that l umbar 
punctur e for CSF is done only 
if clinically indicated.
Secti on 9.1.1, Im aging 
Assessment for the StudyProvi ded extensive addit ional 
details on MRI assessments, 
including related to potential 
leptom eningeal disseminat ion
Secti on 9.2.2, Method of 
Detecting AEs and SAEsDeleted prohibit ion against 
staff asking participant or 
family questions a bout 
specific AEs.
Revised Protocol No.: 01
Date: 11-Sep-2017 7
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 01
Section & Title Description of Change
Secti on 9.4.1, Physical 
Examinat ionsDefined neurologic 
examinat ion as part of 
physical exam.
Secti on 9.5, 
Pharmacokinet ics, Table 9.5 -
1, Ph armacokinet ics and 
Anti-Drug Ant ibody  
Sampling Schedule for 
Nivo lumab; Table 9.5 -2, 
Pharmacokinet ic and Ant i-
Drug Ant ibody  Sam pling 
Schedule for Nivolumab in 
Combinat ion with 
IpilimumabClarified that l umbar 
puncture for CSF is done only 
if clinically indi cated. 
Secti on 10.1, Sam ple Si ze 
Determinat ion Provi ded addi tional detail  on 
the form ula used to cal culate 
the sam ple size.
Secti on 10.3.5, Interim 
AnalysesProvi ded addi tional details 
regarding the interim 
analyses.
All Minor form atting correcti ons, 
cross -refere nces, and edits to 
improve clarit y.
Revised Protocol No.: 01
Date: 11-Sep-2017 8
2.0
Approved
930109651
2.0
v

TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. OVERALL RATIONALE FOR THE REVISED PROTOCOL 01 ............................. SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 01............................ TABLE OF CONTENTS .............................................................................................. 1. SYNOPSIS ................................................................................................................ 2. SCHEDULE OF ACTIVITIES................................................................................. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. OBJECTIVES AND ENDPOINTS .......................................................................... 5. STUDY DESIGN...................................................................................................... 
5.1 Overall Designs ................................................................................................. 
5.1.1 Screening Period ...................................................................................... 5.1.2 Safety Lead-in .......................................................................................... 5.1.3 Definition of Dose-Limiting Toxicity ....................................................... 5.1.4 Expansion ................................................................................................. 5.1.5 Follow-Up Phase ..................................................................................... 5.1.6 Data Monitoring Committee and Other External Committees ................ 
5.1.6.1 Data Monitoring Committee ........................................................... 5.1.6.2 Study Steering Committee ............................................................... 5.1.6.3 Blinded Independent Central Review Committee ........................... 
5.2 Number of Participants ..................................................................................... 5.3 End of Study Definition .................................................................................... 
 
 
 
 
 
 
 
6. STUDY POPULATION ........................................................................................... 
6.1 Inclusion Criteria .............................................................................................. 1
3
4
4
9
1220
39
4040
43
43
44
45
45
45
45
46
47
47
47
52
52Clinical Protocol
BMS-936558CA209908
nivolumab
Revised Protocol No.: 01Date: 11-Sep-2017 9
2.0
Approved
930109651
2.0
v

6.2 Exclusion Criteria ............................................................................................. 
6.3 Lifestyle Restrictions ........................................................................................ 6.4 Screen Failures .................................................................................................. 
6.4.1 Retesting During Screening or Lead-In Period ....................................... 
7. TREATMENT .......................................................................................................... 
7.1 Treatments Administered .................................................................................. 
7.1.1 Module A (Nivolumab Monotherapy): ..................................................... 7.1.2 Module B (Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg Combination): ... 
7.2 Method of Treatment Assignment .................................................................... 7.3 Blinding............................................................................................................. 7.4 Dosage Modification ......................................................................................... 
7.4.1 Dose Delay Criteria ................................................................................. 7.4.2 Criteria to Resume Treatment .................................................................. 7.4.3 Treatment of Related Infusion Reactions ................................................. 
7.5 Preparation/Handling/Storage/Accountability .................................................. 
7.5.1 Retained Samples for Bioavailability / Bioequivalence ........................... 
7.6 Treatment Compliance ...................................................................................... 
 
 
 
 
 
7.8 Treatment After the End of the Study ............................................................... 
8. DISCONTINUATION CRITERIA .......................................................................... 
8.1 Discontinuation from Study Treatment ............................................................ 
8.1.1 Discontinuation of Nivolumab Due to Toxicity [Module A or B] ............ 
8.1.2 Discontinuation of Combination treatment due to Toxicity [Module B] . 
8.1.3 Post Study Drug Study Follow-up............................................................ 
8.2 Discontinuation from the Study ........................................................................ 8.3 Lost to Follow-Up ............................................................................................. 
9. STUDY ASSESSMENTS AND PROCEDURES .................................................... 
9.1 Efficacy Assessments ........................................................................................ 
9.1.1 Imaging Assessment for the Study............................................................ 9.1.2 Suspected Progression ............................................................................. 9.1.3 Assessment of Response ........................................................................... 9.1.4 Results of Central Radiology Assessments .............................................. 
9.2 Adverse Events ................................................................................................. 
9.2.1 Time Period and Frequency for Collecting AE and SAE Information .... 9.2.2 Method of Detecting AEs and SAEs ......................................................... 9.2.3 Follow-up of AEs and SAEs ..................................................................... 9.2.4 Regulatory Reporting Requirements for SAEs ......................................... 9.2.5 Pregnancy ................................................................................................ 9.2.6 Laboratory Test Result Abnormalities ..................................................... 9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................ 9.2.8 Other Safety Considerations .................................................................... 
 54
56
56
56
57
58
59
60
61
61
61
61
62
62
64
64
64
66
66
66
67
69
7070
71
71
72
73
74
75
78
78
78
79
79
79
80
80
81
81Clinical Protocol
BMS-936558CA209908
nivolumab
Revised Protocol No.: 01Date: 11-Sep-2017 10
2.0
Approved
930109651
2.0
v

9.3 Overdose ........................................................................................................... 
9.4 Safety ................................................................................................................ 
9.4.1 Physical Examinations ............................................................................. 9.4.2 Vital signs................................................................................................. 9.4.3 Electrocardiograms ................................................................................. 9.4.4 Clinical Safety Laboratory Assessments .................................................. 9.4.5 Imaging Safety Assessment ...................................................................... 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
9.9 Health Economics OR Medical Resource Utilization and Health Economics . 
10. STATISTICAL CONSIDERATIONS ................................................................... 
10.1 Sample Size Determination ............................................................................. 10.2 Populations for Analyses ................................................................................ 
10.3 Statistical Analyses ......................................................................................... 
10.3.1 Efficacy Analyses ................................................................................... 
10.3.2 Safety Analyses....................................................................................... 
 
 
10.3.5 Interim Analyses ..................................................................................... 
 
12. APPENDICES ........................................................................................................ APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ........................................ APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS ................................. APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW UP AND REPORTING ......................................................................... 
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION ..................................................................... 
 
APPENDIX 6 KARNOFSKY AND LANSKY CRITERIA ........................................ 82
82
82
83
83
83
83
94
94
94
96
96
9699
108109
114
122
126
138Clinical Protocol
BMS-936558CA209908
nivolumab
Revised Protocol No.: 01Date: 11-Sep-2017 11
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
1. SYNOPSIS
Protocol Title: Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in 
Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS 
Malignancies 
Study Phase:
1b/2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 12
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Study Population:
Male and female, age 6 months and 22years old at the time of enrollment , and meet ing one 
of the fo llowing CNS tum or type cri teria:
Parti cipants must have received standard of care therapy , and there must not be potenti ally-
curative treatment available, in one of the following:
1)A newly diagnosed DIPG that has been treated with radiation therapy (RT) but no 
chemotherapy . Diagnosis of DIPG must be confi rmed either based on MRI criteria or 
histol ogy. (Cohort 1)
a)Eligibilit y includes diffuse midline glioma with dem onstrated H3K27 Mmutation
b)Biopsy  is not required for DIPG
c)Enrollment can occur during radiat ion therapy  or up to 4 weeks after end of RT
2)A histol ogically confi rmed recurrent or progressive non-brain stem HGG previ ously treated 
with surgical resect ion and RT(with orwithout chem otherapy ). (Cohort 2)
3)A histol ogically  confirmed medullo blastom a thathas relapsed or is resistant to at least one 
line of prior therapy  including surgery , RT,and chemotherapy (regardl ess of age) (Cohort 3)
4)A histo logically confi rmed ependymo ma that has relapsed or is resistant to at least one line 
of prior therapy including surgical resect ionand RT(regardless of age) .(Cohort 4)
5)A histol ogically -confirmed high grade CNS malignancy “other than above” which is 
recurrent or progressive after at least one line of prior therapy, including for example: 
choroi d plexus carcino ma, germ cell tumor, anapl astic pleomorphic xanthoastrocy toma, 
pineoblastoma, AT/RT , embr yonal tumor with m ultilayered rosettes (ETMR; 
C19MC -altered) that has relapsed or is resistant to at least one line of prior th erapy . (Cohort 
5) 
Note: Participants with any of the above subty pesof high grade CNS tumors are eligible for 
the safet y lead in phase , See Study  Design (Secti on 5.1).
Revised Protocol No.: 01
Date: 11-Sep-2017 13
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Objectives and Endpoints:
Objectives Endpoints
PRIMARY
Safety Lead In
Toestimate thesafety andtolerability ofstudy treatment inpediatric
participants with primary high-grade CNS tumors.Incidence of DLT s, SAEs, and
AEs leading to discontinuation.
Expansion
Toestimate theOS inpediatric participants with newly
diagnosed DIPG. (Cohort 1)OS
Toestimate thePFS inpediatric participants with recurrent or 
progressive HGG .(Cohort 2)PFS
Toestimate thePFSin pediatric participants with relapsed or 
resistant medulloblastoma. (Cohort 3)PFS
Toestimate thePFS inpediatric participants with relapsed or 
resistant ependymoma. (Cohort 4)PFS
Toestimate thePFSinpediatric participants with recurrent or 
progressive other rareCNS tumors (including pineoblastoma,
AT/RT, embryonic CNS tumors) (Cohort 5)PFS
SECONDARY
Safety Lead In
Todescribe anyobserved anti-tumor activity ofstudy treatment in 
pediatric primary high grade CNS tumors.Secondary endpoints are the same 
as in the expansion phase.
Expansion
Toestimate thesafety ofstudy  therapy inpediatric participants with
newly diagnosed DIPG, recurrent or progressive HGG, recurrent or 
progressive medulloblastoma, recurrent or progressive ependymoma and
recurrent or progressive other primary rareCNS tumors .Incidence of AEs, SAEs, drug -
related AEs, AEs leading to 
discontinuation, and death. 
Incidence of laboratory 
abnormalities.
Toestimate thePFS and OSr inpediatric participants with newly
diagnosed DIPG. (Cohort 1 )PFS, OS(12)
Toestimate thePFSr, OS, and OSr and inpediatric participants with
recurrent or progressive HGG. (Cohort 2)PFS(6), OS, OS(12)
Toestimate the PFSr, OS,and OSrinpediatric participants with
recurrent or progressive medulloblastoma. (Cohort 3)PFS( 6), OS, OS(12)
Toestimate thePFSr, OS,and OSrinpediatric participants with
recurrent or progressive ependymoma .(Cohort 4)PFS( 6), OS, OS(12)
Toestimate thePFSr and OS and inpediatric participants with
recurrent or progressive other rareCNS tumors (including
pineoblastoma, AT/RT, other embryonic CNS tumors). (Cohort 5)PFS( 6), OS 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 14
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Objectives Endpoints
   
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
AE = adverse event; AT/RT = atypical teratoid rhabdoid tumor; CNS = central nervous system; DIPG = diffuse 
intrinsic pontine glioma; DLT = dose limiting toxicity ;DOR = duratio n of response; HGG = high grade glioma; 
ORR = objective response rate; OS = overall survival; OSr = overall survival rate; PD = pharmacody namic; PFS 
= progression free survival; PFSr = progression free survival rate; PK = pharmacokinetics; SA E = serious adver se 
event.
Overall Design:
CA209 908 is an open -label, sequential -arm Phase 1b/2 clinical trial of nivolumab monotherapy 
and of nivolumab plus ipilimumab in pediatri c participants with high grade primary CNS 
malignancies. 
Cohorts are defin ed by tumor type (histology):
Cohort 1: N = 22 participants with newly -diagnosed DIPG , including midline glioma with 
H3K27M
Cohort 2: N = 15participants with recurrent or progressive non-brainstem HGG, regardless of 
mutati on status, including glio blastom a
Cohort 3: N = 15 participants with r elapsed or resistant medullo blastoma 
Cohort 4: N = 10 partici pants wi th relapsed or resistant ependymo ma
Cohort 5: N = 18participants with other recurrent subtypes of high-grade CNS malignancy 
(eg,pineoblastoma, AT /RT, germ  cell tum or, and others)
The above intended target numbers for each Module are approximate. 
Revised Protocol No.: 01
Date: 11-Sep-2017 15
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Treatments are defined by Module:
Module A: nivo lumab 3 mg/kg every 2 weeks, as mo notherapy , and 
Module B: nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, ever y 3 weeks for 4 doses followed by 
nivolumab 3 m g/kg every 2 weeks.
Enrollment to Modul e A will open in parallel for all cohorts. Thefirst 6 participants in Cohort 1 
who are treated and DLT eval uable will be evaluated for safety before addi tional parti cipants are
treated in that cohort . Separately, the first 10 participants treated and DLT evaluable in the 
recurrent disease Cohorts 2-5 (combined) will be evaluated for safet y before additional 
participants are treated (see Schema in Figure 5.1-1)in those Cohorts . At regularly -scheduled 
teleconferences , the Study  Steering Committee (SSC)will review safet y, assess potenti al DLTs, 
and make recommendations regarding reopening of enro llment.
Based on determinat ion of adequate safet y, enrollment will re-open for evaluat ion of efficacy to 
complete the planned number of participants for each cohort in Modul e A expansi on. 
Parti cipants evaluated in the safety lead-in will be included for evaluat ion of efficacy (ie, the 
6participants with DIPG evaluated for safet y in Cohort 1 are included in the 22 planned 
participants).
Enrollment will begin in Modul e B, by cohort, based on completion of planned accrual in 
Module A or a decisio n of the SSC (see Section 5.1.6.2 ); therefore, accrual will not open in 
parallel for Module B. Invest igators will be informed when Module B is open. For Module B, the 
first 10 participants treated and DLT evaluable in all cohorts combined will be evaluated for 
safet y by the SSC before additional participants are enrolled (see Schema in Figure 5.1-1) after 
which cohorts will be re- opened for full accrual in the expansio n.
Parti cipants will be cl osely m onitored f or AEs throughout the study using clinical and laboratory 
evaluat ions (see Sections 2 and 9 for details). The SSC (seeSection5.1.6.2) will meet regul arly 
during the study  to ensure that participant safet y is carefully mo nitored.
Tumor progression or response endpo ints will be assessed using Radiologic Assessment in 
Neuro -Oncology criteria (RANO) 2010 described in Section 9.1.3, as as sessed by Invest igator.
Blood sam ples will be obtained prior to and post drug administration for PK and bio markers. The 
PK sampling schedule for monotherapy  and combinat ion therapy  are provi ded in Table 9.5 -1 and 
Table 9.5 -2, respectively. 
After discont inuation of study treatm ent, all participants will be followed for safety, tumor 
progression, and OS (see Section 5.1.4 ).
Number of Participants:
Enrolled 176-200 (88-100 for nivolumab monotherapy; 88-100 for nivolumab + 
ipilimumab combination)
Revised Protocol No.: 01
Date: 11-Sep-2017 16
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Treat ed 160 (80 for nivolumab monotherapy ; 80for nivolumab + ipilimumab 
combinat ion)
Screen Failure Rate 10 -25%
Cohort sA1and B1:Sample sizes of 22 participants for each ofthe Cohorts A1and B1
in DIPG is based on compar ison of OSagainst anhistorical control of median OS 
9months, assuming 80% power, 1-sided alpha of 10%, target median OS of 15months, 
and a one-sample log rank test. All distributi ons are assumed to be exponent ial; assume 
12months for accrual and 24 months for fo llow-up.
Cohorts A2 and B2:Sample sizes of 15participants for each of the Cohorts A2and B2
in HGG is based on anhistori cal PFS(6) of  18%, one -year accrual , one year follow-up, a 
target PFS(6) of 38%providing 80% power using a one-sided Type 1 error of 10%, 
assuming an exponent ial distribution.
Cohort A3and B3:Sample sizes of 15 participants for each of the cohorts is based on 
comparison of  PFS against a nhistori cal control  of PFS rate at 4 m onths of  .18, assuming 
80% power, 1-sided alpha of 10%, target PFS rate at 4 months of .38, and a one -sample 
log rank test. All distribut ions are assumed to be exponent ial; assume 12months for 
accrual and 12 months fo llow-up.
Cohort A4 and B4:Sample sizes of 10participants for each of the cohorts is based on 
comparison of PFS against anhistori cal control  of median PFS of 2.1months, assuming 
80% power, 1-sided alpha of 10%, target median PFS of4.4 months, and a one-sample 
log rank test. All distribut ions are assumed to be exponent ial; assume 12months for 
accrual and 12 months fo llow-up.
Cohort A5 and B5:Sample sizes of 18participants for each of the Cohorts A5 and B5 is 
not based on statistical considerati ons as these cohorts contain various tumor types. 
However, if the disease control  rate at 12 months is 30%, 18 patients provide 21% 
preci sion for the est imate.
Treatment Arms and Duration:
Study treatment :
Study Drug for CA209908
Medication Potency IP/Non -IP 
Nivolumab
(BMS -936558-01) Solution for 
Injectiona100 mg (10 mg/mL) IP
Ipilimumab
(BMS -734016)
Solution for Injection200 mg (5 mg/mL) IP
Revised Protocol No.: 01
Date: 11-Sep-2017 17
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
aMay be labeled as either “BMS -936558-01” or “Nivolumab”
Revised Protocol No.: 01
Date: 11-Sep-2017 18
2.0
Approved
930109651
2.0
v

Clinical Prot ocol CA209908
BMS -936558 nivolumab
Figure 1-1: Overall Study Design Schematic
A2 Recurrent High -Grade 
Glioma/GlioblastomaA1 Newly -diagnosed 
Pontine Glioma, post -RT
A3 Recurrent 
Medulloblastoma
A4 Recurrent Ependymoma
A5 Recurrent High -Grade 
Other Histologies
Notes: 
•Cohorts are indicated by tumor type; Study T reatments are indicated as A = nivolumab and B = nivolumab + ipilimumab
•Safety is evaluated across cohorts (indicated as “lead -in”), prior to expansion
•Efficacy is evaluated bycohort (indicated as Expansion), including lead- in population
•Module B opens , by cohort , when corresponding Module A is completed or upon decision of Steering CommitteeSafety 
lead -in
N = 10N = 6
B2 Recurrent High -Grade 
Glioma/GlioblastomaB1 Newly -diagnosed 
Pontine Glioma, post -RT
B3 Recurrent 
Medulloblastoma
B4 Recurrent 
Ependymoma
B5 Recurrent High -Grade 
Other HistologiesExpansion
N = 15
N = 15N = 22Safety 
lead- inExpansion
N = 15N = 22Efficacy analysisSafety analysis
N = 10
N = 18N = 10N = 15
N = 18N = 10
Efficacy analysisSafety analysis
Revised Protocol No.: 01
Date: 11-Sep-2017 19
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
2. SCHEDULE OF ACTIVITIES
Screening assessments for this study  are summarized in Table 2.-1, On -treatm ent procedures for 
Module Ain Table 2.-2 and for Modul e B in Table 2.-3, and Follow -Upprocedures for both 
Modules A and B in Table 2. -4. Schematics for Treatm ent and Key Assessments are provi ded in 
Figure 2.-1 and Figure 2.-2 for Modules A and B, respectively . Detailed schedule s for 
pharmacokinet ic (PK) and immunogenicit y sampling are provided (Modules A and B, 
respectively ) in Table 9.5-1and Table 9.5-2and for biomarker sampling inTable 9.8-2and
Table 9.8 -3.
Addit ional diagnosti c procedures and laboratory tests not required by protocol  should be 
perform ed as clinically- indicated; these resul ts may be included in study  data. Any clinically -
appropriate intervent ion shoul d be done, regardless of protocol  requirement, for optimal 
management of each study  parti cipant.
Revised Protocol No.: 01
Date: 11-Sep-2017 20
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 2. -1: Screening Procedural Outline (CA209908)
Procedurea Screening
VisitNotes
Informed Consent XRegister in Interactive Response System to obtain participant number ; then again prior to 
treatment start if fully eligible (see instructions provided in manual )
Inclusion/Exclusion Criteria X Must be confirmed prior to treatment
Medical History X
Tumo r Sample Submission XTumo r tissue, either FFPE block or a minimum of 20 slides from recent surgery if performed; 
archival tissue is required if no recent surgery done. (See Section 6.1; not required for DIPG )
Sample should be sent with an institutional p athology report . Additional molecular information 
will be collected.
Physical Examination (including vital signs 
&performance status)XInclude BP, HR, RR, temperature , and neurological exam at screening and within 72 hours prior 
to treatment 
Within 14 days prior to treatment: Height, weight, and Lansky play score (LPS) for 16 years or 
Karnofsky performance scale (KPS) for > 16 years of age.
Assessment of Signs and Symptoms X Within 14 day s prior to treatment assignment .
Steroid Dose Documentation X Within 14 days prior to treatment assignment .
Serious Adverse Events Assessment X See Appendix 3 .
Laborato ry Tests XWithin 14 days prior to treatment : CBC w/differential; Chemistry panel (see Section 9.4.4 ).
Within 28 days prior to treatment: Thyroid panel and Hepatitis B/C serology (see Section 9.4.4).
Screening/Baseline Tumor Assessment XContrast -enhanced MRI must be performed within 21 days prior to study treatment (see Imaging 
Manual). Complete MRI of the spine performed per clinical indication. See Section 9.1.1 .
CSF cy topathology  per clinical indication up to 7 days before treatment start. See Section 9.8.1 .
In Coho rt 1, MRI must be performed after RT and prior to study treatment; prior diagnostic
MRI scan also will be collected. 
aSome of the assessments referred to in this section may  not be captured as data in the eCRF. They  are intended to be used as safety monitoring by the treating 
physician. Additio nal testing o r assessments may  be performed as clinically necessary or where re quired by institutional or local regulations. If a participant is 
referred from another institution, assessments that were completed at the referring institution can be used as the screening assessments. 
Revised Protocol No.: 01
Date: 11-Sep-2017 21
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 2. -2: Nivolumab Monotherapy [Module -A] Procedural Outline (CA209908)
ProcedureCycle 1 and 
subsequent cyclesaNotesb
(Cycle duration = 2 weeks unless treatment is delayed)
Targeted Physical Examination, Vital 
Signs, Weight and Performance StatusXTo be performed within 72 hours of dosing. Physical and neurologic exam at C1D1 and as 
clinically indicated. See Section 9.4.1 . VS (BP, HR, RR and temperature, weight) within 
72 hours prior to dose. Lansky play score (LPS) for 16 years or Karnofsky performance 
scale (KPS) for > 16 years.
Adverse Event assessment Continuously Record at each visit. Assessed using NCI CTCAE v. 4.
Laborato ry Tests XWithin 72 hours prior to each dose. Include CBC w/differential, ALT, AST, T -Bili, BUN 
or seru m urea, creatinine, Na, K, Cl, glucose.
TSH ever y 6 weeks with reflexive Free T4 and Free T3 if TSH abnormal.
Laborato ry tests do not need to be repeated on C1D1 if done within 14 days prior to dose. 
Pregnancy Test (WOCBP only) XSerum or urine (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours 
prior to first dose then at least once every 4 weeks ( 1week) regardless of delays.
Tumo r AssessmentX 
(See note)Contrast enhanced MRI after 6 & 12 w ks(1 week ) then Q 8 w ks (1 week) X 4, then 
Q 12 w ks (1 week), or earlier if clinically indicated. NOTE: Post -RT MRI required in 
Cohort 1. MRI of the spine also performed per clinical indication. See Section 9.1.1 .
Tumo r Tissue, on -study sampleX
(See note)If biopsy or resection is performed at suspected progression, tumor sample (block or slides) 
should be submitted to central laboratory. (See Section 9.8.5)
 
Dispense Study Drug X First dose within 3 calendar days of treatment assignment. 
aIf dose is delay ed, the procedures scheduled for that same time point (except tumor assessments which should follow the specified schedule) should also be 
delayed to coincide with when that time point’s dosing actually occurs .
bSome of the assessments referred to in this section may  not be captured as data in the eCRF. They  are intended to be used as safety monitoring by  thetreating 
physician. Additional testing or assessments may be performed as clinically necessary or wh ere required by institutional or local regulations.
Revised Protocol No.: 01
Date: 11-Sep-2017 22
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Figure 2. -1: Module A Treatment and Key Assessments
Module A: Treatment & Key Assessments
PK
ADA
BiomarkersX1 3 7 13 15 17 19 21 25 29
week
MRI scan5 11 9
MRI scan: pre-study, q6 wk x 2, then q8 wkNivolumab
PK: pre-dose & EOI;ADA samples
Biomarker samples ; see Table for detailXTumor  sample; and if surgery on-study or at P DThis Figure is for overall guidanc e, and 
does not include (eg) trea tment delay, 
unscheduled assessments, etc.Thyroid FnCBC & Chems
Local lab tests, repeat  as clinically indicatedTreatment  
[cycle]
Revised Protocol No.: 01
Date: 11-Sep-2017 23
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 2. -3: Nivolumab + Ipilimumab combination [ Module B ]Procedural Outline (CA209908)
ProcedureCycles 1-4a
(Cycle = 3 weeks)Cycle 5 and beyon da
(Cycle = 2 weeks)Notesb
Targeted Physical Examination, 
Vital Signs, Weight and 
Performance StatusX XTo be performed within 72 hours of dosing .Physical and neurologic exam
at C1D1 and as clinically indicated. See Section 9.4.1 , VS (BP, HR, RR 
and temperature, weight) within 72 hours prior to dose. Lansky play score 
(LPS) for 16 years or Karnofsky performance scale (KPS) for > 16 years.
Adverse Events Assessment Continuously Record at each visit using NCI CTCAE v. 4 .
Laborato ry Tests X XWithin 72 hours prior to each dose. Include CBC w/differential, ALT, AST, 
T-Bil i, BUN or serum urea, creatinine, Na, K, Cl, glucose, amylase, and 
lipase.
TSH ever y 6 we eks with reflexive Free T4 and Free T3 if TSH is abnormal .
Laborato ry tests do not need to be repeated on C1D1 if done within 14 days 
prior to dose.
Pregnancy Test (WOCBP only) X XSerum or urine pregnancy test ( minimum sensitivity 25 IU/L or equivalent 
units of HCG) within 24 hours prior to first dose then at least once ever y 
4weeks (1 week) regardless of dose delays.
12-Lead ECG X X Only as clinically indicated .
Tumo r Assessment X(See note )Contrast enhanced MRI after 6 & 12 weeks (1 week )then Q8 week s (
1 week) X 4, then Q12 weeks , (1 week) or earlier if clinically indicated. 
Post-RT MRI required in Cohort 1. MRI of the spine also performed per 
clinical indication. See Section 9.1.1 .
 
Dispense Study Drug X(combination) X(monotherapy ) First dose within 3 calendar days of treatment assignment.
Revised Protocol No.: 01
Date: 11-Sep-2017 24
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
aIf a dose is delayed, the procedures for that same time point should also be delay ed to coincide with when that time point’s dosing actually occurs, except 
tumor assessments which should follow the specified schedule. Cycle 5 begins 3 weeks after Cycle 4
bSome of the assessments referred to in this section may not be captured as data in the eCRF. They  are intended to be used as safety monitoring by  the treating 
physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or l ocal regulations.
Revised Protocol No.: 01
Date: 11-Sep-2017 25
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Figure 2. -2: Module B Treatment and Key Assessments
Module B: Treatment & Key Assessments
Treatment  
[cycle]1 4 7 10 13 15 17 19 21 25 29
week
MRI scan
PK
ADA
BiomarkersTumor TissueX
Thyroid FnCBC & Chems
Ipilimumab
MRI scan: pre-study, q6 wk x 2, then q8 wkNivolumab
PK: pre-dose & E OI;ADA samples
Biomarker s amples ; see Table for det ailXTumor  sample;  and if  surgery on-study or at PDLocal lab tests, repeat  as clinically indicated
This Figure is for overall guidance, and  
does not include (eg) trea tment delay, 
unscheduled assessments, etc.
Revised Protocol No.: 01
Date: 11-Sep-2017 26
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 2. -4: Follow -up Procedural Outline (CA209908)
Procedure Follow -upVisits 1 & 2aSurvival Visitsb Notesc
Targeted Physical Examination X
Adverse Events Assessment X XDrug -related adverse events will be followed until resolved or 
returned to baseline. See Section 9.2.3 .
Serious Adverse Events Assessment X
Laborato ry Tests XCBC w/differential, LFTs, T. Bili, BUN, creatinine , Na, K, Cl, 
glucose and TSH for follow -up #1, repeat labs at follow -up #2 if 
study drug -related toxicity persists.
Pregnancy Test WOCBP only X Serum or Urine .
Survival Status X XEvery 3 months (clinic visit or telephone contact), during Survival 
phase, include documentation of subsequent chemotherapy .
Tumo r Assessment X XParticipants who did not prog ress wh ile on study t reatment should 
continu e MR I follow -up according to the schedule in Table 2. -2and
Table 2. -3, or earlier if clinically indicated , regardless of subsequent
therapy.MRI of the spine and CSF cytopathology also performed 
per clinical indication.
Tumo r tissue , on-study sample X XIf biopsy or surgical resection is performed at suspected progression, 
a tumo r sample (block or slides) should be submitted to central 
laborato ry.
aParticipants must be followed forat least 100 days after last dose of study treatment. Follow -up visit #1 should occur 30 days from the last dose (7 days) or 
can be performed on the date of discontinuatio n if that date is greater than 42 day s from the last dose. Follow -up #2 occurs appr oximately 100 days ( 7 days)
after the last dose of study treatment. Both follow -up v isits should be conducted in person.
bSurvival visits to occur every 3 months (14 days) from Follow -up visit 2. May be conducted in person or by telephone. BMS may request that survival data 
be collected on all treated participant s outside of the 3 month specified window. At the time of this request each participa nt will be contacted to determine 
their survival status unless the participant has withdrawn consent for all contact.
Revised Protocol No.: 01
Date: 11-Sep-2017 27
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
cSome of the assessments referred to in th is section may not be captured as data in the eCRF. They  are intended to be used as safety monitoring by  the treating 
physician. Additional testing or assessments may be performed as clinically necessary or wh ere required by institutional or local regulati ons.
Revised Protocol No.: 01
Date: 11-Sep-2017 28
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
4. OBJECTIVES AND ENDPO INTS
Table 4. -1: Objectives and Endpoints
Objectives Endpoints
PRIMARY
Safety Lead In
Toestimate thesafety andtolerability ofstudy treatment inpediatric
participants with primary high-grade CNS tumors.Incidence of DLTs, SAEs, and AEs 
leading to discontinuation.
Expansion
Toestimate theOS inpediatric participants with newly
diagnosed DIPG. (Cohort 1)OS
Toestimate thePFS inpediatric participants with recurrent or 
progressive HGG .(Cohort 2)PFS
Toestimate thePFSinpediatric participants with relapsed or 
resistant medulloblastoma. (Cohort 3)PFS
Toestimate thePFS inpediatric participants with relapsed 
or resistant ependymoma. (Cohort 4)PFS
Toestimate thePFSinpediatric participants with recurrent
or progressive other rareCNS tumors (including
pineoblastoma, AT/RT, embr yonic CNS tumors) (Cohort 5)PFS
SECONDARY
Safety Lead In
Todescribe anyobserved anti-tumor activity ofstudy treatment in 
pediatric primary high -grade CNS tumors.Secondary endpoints are the same as 
in the expansion phase.
Expansion
Toestimate thesafety ofstudy  therapy inpediatric participants with
newly diagnosed primary DIPG, recurrent or progressive HGG,
recurrent or progressive primary medulloblastoma, recurrent or 
progressive primary ependymoma andrecurrent or progressive other 
primary rareCNS tumors .Incidence of AEs, SAEs, drug -
related AEs, AEs leading to 
discontinuation, and death. 
Incidence of laboratory 
abnormalities.
Toestimat ethePFS and OSr inpediatric participants with newly
diagnosed DIPG. (Cohort 1 )PFS, OS(12)
Toestimate thePFSr, OS,and OSr and inpediatric participants with
recurrent or progressive HGG. (Cohort 2)PFS(6), OS, OS(12)
Toestimate the PFSr, OS,and OSrinpediatric participants with
recurrent or progressive medulloblastoma. (Cohort 3)PFS( 6), OS, OS(12)
Toestimate thePFSr, OS,and OSrinpediatric participants with
recurrent or progressive ependymoma .(Cohort 4)PFS( 6), OS, OS(12)
Toestimate thePFSr and OS and inpediatric participants with
recurrent or progressive other rareCNS tumor s (includin g
pineoblastoma, AT/RT, other embryonic CNS tumors). (Cohort 5)PFS( 6), OS 
Revised Protocol No.: 01
Date: 11-Sep-2017 39
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 4. -1: Objectives and Endpoints
Objectives Endpoints
EXPLORATORY
 
  
 
 
  
 
 
 
  
 
 
  
 
 
 
 
AE = adverse event; AT/RT = atypical teratoid rhabdoid tumor; CNS = central nervous system; DIPG = diffuse 
intrinsic pontine glioma; DLT = dose limited toxicity; DOR = duratio n of response; HGG = high grade glioma; 
ORR = objective response rate; OS = overall survi val; OSr = overall survival rate; PD = pharmacodynamic; PFS 
= progression -free survival; PFSr = progr ession -free survival rate; PK = pharmacokinetics; SAE = serious 
adverse event.
5. STUDY DESIGN
5.1 Overall Design s
CA209 908 is an open -label, sequential -arm Phase 1b/2 clinical trial of nivolumab monotherapy 
and of nivolumab plus ipilimumab in pediatric participants with high-grade primary CNS 
malignancies. 
Cohorts are defined by tumor type (histology):
Cohort 1: N = 22 participants with newly -diagnosed DIPG ,including midline glioma with 
H3K27M m utation
Cohort 2: N = 15participants with recurrent or progressive non-brainstem HGG, regardless of 
mutati on status, including glio blastom a
Cohort 3 : N = 15 participants with relapsed or resistant medullo blastoma 
Cohort 4 : N = 10 participants with relapsed or resistant ependymo ma
Revised Protocol No.: 01
Date: 11-Sep-2017 40
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Cohort 5: N = 18participants with other recurrent subtypes of high-grade CNS malignancy 
(eg,pineoblastoma, AT /RT, germ  cell tum or, and others)
The above intended target numbers for each Module are approximate. 
Molecular phenoty pe analyses will be performed according to institutional standard. Details on 
the molecular subt ype o f the individual tumors will be reported when they beco me available.
Treatments are defined by Module:
Module A: nivolumab 3 mg/kg every 2 weeks, as mo notherapy , and 
Module B :nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, every 3 weeks for 4 doses followed by 
nivolumab 3 m g/kg every 2 weeks.
Enrollment to Modul e A will open in parallel for all cohorts. Thefirst6 participant s in Cohort 1
who are treated and DLT eval uable will be evaluated for safet y before addi tional parti cipants are 
treated in that Cohort. Separately ,the first 10participant s treated and DLT evaluable in the
recurrent disease Cohort s 2-5 (combine d) will be evaluated for safet y before additional 
participants are treated (see Schema inFigure 5.1-1) in those Cohorts . At regularly -scheduled 
teleconferences , the Study  Steering Committee (SSC)will review safety, assess potenti al DLTs, 
and make recommendat ions regarding reopening of enrollment. See additional details in Section 
5.1.2 .
Based on determinat ion of adequate safet y, enrollment will re-open for evaluat ion of efficacy to 
complete the planned number of participants for each cohort in Modul e Aexpansio n. 
Parti cipants evaluated in the safety  lead-in will be included for evaluat ion of efficacy (ie, the 
6participant s with DIPG evaluated for safet y in Cohort 1 are included inthe 22 planned 
participants).
Enrollment will begin inModul e B, by cohort, based on completion of planned accrual in 
Module A or a decisio n of the SSC (see Secti on 5.1.6.2 ); therefore, accrual will not open in 
parallel for all cohorts into Modul e B.Invest igators will be informed when Modul e B is open. 
For Module B, the first 10 participant s treated and DLT evaluable in all cohorts combined will 
be evaluated for safet y by the SCC before additi onal partici pants are enrolled in all cohorts 
combined will  be evaluated for safety  by the SSC before addi tional parti cipants are enrolled (see 
Schema inFigure 5.1-1) after which cohorts will be re-opened for full accrual in the expansio n. 
(NOTE: An individual part icipant may not enroll in more than one Module.)
Revised Protocol No.: 01
Date: 11-Sep-2017 41
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Figure 5. 1-1: Overall Study Design Schematic
A2 Recurrent High -Grade 
Glioma/GlioblastomaA1 Newly -diagnosed 
Pontine Glioma, post -RT
A3 Recurrent 
Medulloblastoma
A4 Recurrent Ependymoma
A5 Recurrent High -Grade 
Other Histologies
Notes: 
•Cohorts are indicated by tumor type; Study T reatments are indicated as A = nivolumab and B = nivolumab + ipilimumab
•Safety is evaluated across cohorts (indicated as “lead -in”), prior to expansion
•Efficacy is evaluated bycohort (indicated as Expansion), including lead -in population
•Module B opens , by cohort , when corresponding Module A is completed or upon decision of Steering CommitteeSafety 
lead-in
N = 10N = 6
B2 Recurrent High -Grade 
Glioma/GlioblastomaB1 Newly -diagnosed 
Pontine Glioma, post -RT
B3 Recurrent 
Medulloblastoma
B4 Recurrent 
Ependymoma
B5 Recurrent High -Grade 
Other HistologiesExpansion
N = 15
N = 15N = 22Safety 
lead -inExpansion
N = 15N = 22Efficacy analysisSafety analysis
N = 10
N = 18N = 10N = 15
N = 18N = 10
Efficacy analysisSafety analysis
Revised Protocol No.: 01
Date: 11-Sep-2017 42
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Parti cipants will be closely monitored f or AEs throughout the study using clinical  and laboratory 
evaluat ions (see Secti ons 2and 9for details ).The SSC (see Section 5.1.6.2 ) will meet regularly 
during the study  to ensure that participant safet y is carefully mo nitored.
Tumor progression or response endpo ints will be assessed using Radiologic Assessment in 
Neuro -Oncology criteria (RANO) 2010 described in Section 9.1.3 , as assessed by Invest igator.
Blood sam ples will be obtained prior to and post drug administration for PK and biomarkers . The 
PK sampling schedule for monotherapy  and combinat ion therapy  are provi ded in Table 9.5 -1and 
Table 9.5 -2, respectively. 
After discont inuat ion of study treatment, all participants will be followed for safety, tumor 
progression, and survival (see Secti on 5.1.5 ).
5.1.1 Screening Period
Screening procedures are provided inTable 2.-1. Procedures which are standard of care may be 
perform ed pri or to Inform ed Consent. See S ection 7.2for Treatment Assignment .
Parti cipants in Cohort 1 may be enrolled at any time from diagnosi s until 4weeks after 
completion of RT. (RT is not specified by protocol , but is considered standar d of care.)For 
participants in Cohort 1, study treatm ent must beinitiated within a maximum of 6  w eeks 
post-RT.The screening period for participants in Cohorts 2 -5 may be up to 4 weeks as needed. 
For all Cohorts, study  treatment should begin wit hin 3 da ys after assignment of study treatment. 
All molecular informat ion about the tumor will be entered on the case report form when it 
beco mes available (not required for treatment start). Testing for genetic or molecular features
(eg, H3K27M mutation, BRAF mutation, RELA -fusion, etc) is not performed centrally but will 
be perform ed according to institutional procedures. 
5.1.2 Safety Lead -in
A safet y lead-in will be implemented because nivol umab , as monotherapy  or immediately after 
RT or in combinat ion with ipilimumab ,has not been studied in pediatri c partici pants with CNS 
tumors.
In Modul e A, 6 participant s with newly -diagnosed DIPG (Cohort 1) will be evaluated for safet y 
of nivolumab administered following RT and 10 participants with recurrent CNS tumors will be 
evaluated for safet y of nivolumab monotherapy . Tolerabilit y and safet y of the treatm ent will be 
determined after theseparticipan tshave completed 3doses and aminimum of 6 weeks on study
or discont inued duetodose-limit ing toxicity(DLT; see Section 5.1.3 ). Safetyevaluat ion will be 
conducted based on criteria described in Secti ons9.2and 9.4. Enrollment will proceed to 
expansio n for Modul e Aonly if not more than 2 DLTs are observed in Cohort 1, and separately 
only if not m ore than 3 DLTs are o bserved among the 10 participants in Cohorts 2-5. If no DLTs 
are observed in the first 5 (of 6)participants in Cohort 1 or in the first 8(of 10) participants in 
Cohorts 2-5, then after review bythe SSC, enrollment to corresponding Expansio n phase may 
proceed. Participants who discont inue study  treatment prior to 3doses for reasons other than 
drug-related toxicit iesare not evaluable for DLT and willbe repl aced.
Revised Protocol No.: 01
Date: 11-Sep-2017 43
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
If exact ly 2 DLTs are observed in Cohort 1 or exactly 3 DLTs are observed in Cohorts 2-5, the 
SSC will make a determinat ion as to continuat ion of enrollment based on the nature, severit y,
and reversibilit y of the AEs observed. In this circum stance, enrollment will be stopped until the 
DMC has agreed.
In Modul e B, 10 parti cipants f rom any Cohort (ie, those f or which Modul e A has cl osed) will be 
evaluated for safet y of nivo lumab in combinat ion with ipilimumab. Tol erabili ty and safety  of the 
treatm ent willbe determined after these participants have completed 2doses andobserved for a 
minimum of 6 weeks or di scont inued due to DLT . Safet y evaluat ion will be conducted based on 
criteria described in Sections 9.2and 9.4. If not more than 3 DLTs are observed among the 
10participants in Cohorts 1-5, enrollment will proceed into expansion for Modul e B. 
Parti cipants who are not evaluable for DLT will be repl aced.The same condi tion as noted above 
will be implemented if exact ly 3 DLTs are observed in this safet y populati on.
The SSC will review safet y informat ion in order to determine closure and re-opening of 
enrollment by Cohort. Safety and tolerabili ty beyond i nitial dosing may also be taken into 
consideration.
5.1.3 Definit ion of Dose -Limiting Toxicity
A dose limit ing toxicity (DLT )is defined as a drug-related AE occurring in the first 6 weeks of 
study  treatm ent. A participant will be consi dered evaluable for a DLT if study  treatment was 
delayed > 2 weeks or was discont inued due toa related AE,or if planned study  treatm ent 
(3doses of nivolumab in Modul e A, 2 doses of nivolumab plus ipilimuma b in Modul e B) was 
administered and safet y evaluat ion after 6 weeks on study is available to the SSC.Participants 
who discont inue treatm ent for a reason other than toxicity (ie,without DLT) are not evaluable 
for DLT and will be replaced in enro llment. 
The Sponsor and SSC will determine whether a toxicit y qualifies as DLT. In addition, the SSC 
may consider AEs occurring after 6 weeks o fstudy  in assessment of overall tolerabilit y.
DLTs will be assessed separately  for Cohort 1 because the anatomic location of DIPG and the 
administration of study treatment shortly after RT may create additional risks of 
immune -treatm ent effect. The frequency of DLTs will be assessed as a group for participants 
with recurrent or progressive CNS tumors (Cohorts 2 -5). 
The fo llowing drug -related AEs will be considered DLT:
Any Grade 3 clinical toxicity including:
Grade 3 non -neurologic AE of any durat ion
Grade 3 neurologic AE consistent with immune -treatm ent effect (ie, associ ated with 
tumor locati on, but not consistent with progressive disease) and no t resolved to Grade 0 -1 
within 14 day s despi te appropriate treatm ent
Grade 2 uveit is (eg,with eye pain or blurred visio n) that does not respond to topical 
therapy  (ie, improved to Grade 0 -1 within 14 days) or requires systemic treatment
Except ion: fever or vomit ing lasting < 72 hours is not a DLT
Revised Protocol No.: 01
Date: 11-Sep-2017 44
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Any Grade 3 laboratory  value not resolved to Grade 0 -1 within 14 days, except
Elevat ion of AST, ALT or total bilirubin of any duration
DILI (AST or ALT >3 x ULN with total bilirubin >2 x ULN) of any duration
Any Grade 4 laboratory  value, except the following are not DLT
lipase or amylase without associated symptoms
lymphocy topeni a
electroly te abnorm ality lasting < 72 hours
Any IMAE, regardl ess of Grade, which requires discontinuati on of study treatm ent 
(eg,pneumonit is, hypersensit ivity react ion, acu te kidney injury) will be a DLT.
5.1.4 Expansion
After acceptable safety  has been established inthesafet y lead-in, enrollment will continue in the 
expansio n.
In Modul es A andB, study therapy  (see Secti on7.1) will  be administered to the total  numbers of 
participants per Cohort given in Section 5.1. Parti cipants evaluable for efficacy  who were treated
in the safet y lead-in will be included in the total number planned for expansion .
5.1.5 Follow -Up Phase
The follow-up phase begins when the decision is made to discontinue a participant from study 
treatm ent(see Secti on 8.1), including for AEs, for maximum clinical benefit (investigator 
decisio n), for participant request, disease progression, or another reason.
Parti cipants will be evaluated for AEs with visits at 30days (7 days)from the last dose of 
study  drug or can be performed on the date of  discontinuat ion if that date is greater than 42 days 
from the last dose. F ollow -up visi t #2 occurs approximately 100 days (7 days) after l ast dose of 
drug; for details, see Table 2. -4and Sect ion 9.2. All AEs must be documented for a minimum of 
100days after discont inuat ion, but drug-related toxicit ies shoul d continue be followed until they 
resolve, return to baseline ,or are deemed irreversible. 
Parti cipants who discont inue treatm ent for a reason other than disease progressi on will continue 
to undergo tumor assessments according to the schedul e inTable 2. -2and Table 2. -3,or earlier if 
clinically indicated, regardless of subsequent therapy . Introduction of anti-tumor therapy  in the 
absence of prog ression is strongly discouraged.
Regardless of subsequent therapy , a minimum observat ion time of 3 years is planned for long-
term survivors.
5.1.6 Data Monitoring Committee and Other External Committees
Three independent committees will be utilized: aSSC, a da ta monitoring committee (DMC) and 
a Blinded Independent Central Review Co mmittee (BICR ).
5.1.6.1 Data Monitoring Committee
A Data Moni toring Commit tee will be established to provide oversight of safetyand to provide 
advice to the sponsor regarding actions the committee deems necessary  for the continuing 
Revised Protocol No.: 01
Date: 11-Sep-2017 45
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
protecti on of participant s. The DMC will be charged with assessing such actions in light of an 
acceptable benefit/risk profile for nivolumab. The DMC will act in an advisory  capacit y to BMS 
and will monitor participant safet y and evaluate the available efficacy  data for the study. The 
oncol ogy therapeutic area of BMS has primary  responsibilit y for design and conduct of the 
study . The DMC will meet at least every 6 months or more frequent ly as needed on an adhoc 
basis. Inform ation regarding DMC membership, responsibilit ies, and procedures are detailed in 
the DMC charter. The DMC will be informed should a safet y signal emerge and may convene an 
ad-hoc meet ing on its own initiative. Any major recommendat ion of the SSC will be 
communicated to the DMC. When requi red, adjudicated events will be submitted to the DMC 
and Health Authori ties for review. The DMC will review all available data (safet y and efficacy) 
data at each meet ing. At the concl usion of each DMC meet ing,the committee will provi de the 
sponsor with a recommendation to continue, modify or terminate the study  protocol  based upon 
their review. Ultimately, decisi ons regarding the study  protocol  will bemade by the sponsor in 
conjunction with advice from the SSC and the DMC.
5.1.6.2 Study Steering Committee 
A SSC will be utilized. The SSC will be comprised of subject matter experts, with chairman 
representation from each of the Cooperative Groups (eg, COG and ITCC ). They  will provide 
guidance for study  design and input as needed throughout the course of the study  including 
oversight of safety and efficacy considerati ons, study conduct, and risk-benefit ratioin protocol 
CA209 -908 (See Section 10.3.5 ).Any majo r recommendat ion of the DMC will be 
communicated to the SSC.
The Steering committee may reco mmend to: 
1) T erminate or continue accrual to any cohort for safet y or efficacy reasons, and overall 
clinical risk/benefit considerations. 
a)a test for fut ility, as defined in Section 10.3.5
b)any of Cohorts 2-5 may be stopped at discret ion of Steering Commit tee; for example, a 
cohort wouldbe considered for closure if 0/9 evaluable participants experience an 
objective response
c)keep accrual open beyo nd the stated target number of participants in any Cohort , for 
example, in order to study a sub-populati on with preliminary  evidence of benefi t
(requires Amendment)
d)proceed to Expansio n phase based on safet y criteria (Secti on 5.1.2 ) 
2)Open a newl y-diagnosed HGG cohort, contingent on safet y and preliminary efficacy  in 
recurrent HGG , or another cohort based on new information (requires A mendment)
3)Implement any  clinically -indicated safet y modificati ons (eg ,prolonging infusio n durat ion) to 
be effecti ve immediately , pending distribut ion of an Amendment.
Following review, the SSC will reco mmend cont inuation, modification, or discont inuat ion of this 
study  based on reported safet y and efficacy data.
Revised Protocol No.: 01
Date: 11-Sep-2017 46
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
5.1.6.3 Blinded Independent Central Review Committee
The clinical management of participants during the study  protocol  will be based upon local 
radiologic tumor measurements and the invest igator -assessed RANO response criteria described 
in Section9.1.3 . Radiologic imaging from this study  will also be transmitted to a centralized 
imaging core lab for storage and sponsor access. Imaging will be analyzed for PFS and response 
by a BICR as deter mined by the sponsor. Details of the BICR responsibilit ies and procedures 
will be specified in the Blinded Independent Central Review charter.
5.2 Number of Participants
A complete descri ption of the sample size is provided in Secti on 10.1.Up to 200participants are 
planned to be enrolled and screened, with up to 100in Module A and 100in Module B to include 
up to 80 participants treated per module.
5.3 End of Study Definition
This study  will consist of safety lead in and expansio n; and 3 periods: screening, treatm ent, and 
follow-up. The start of the trial is defined as the first visit for the first screened participant. The 
end of the trial is defined as the last scheduled procedure shown in the Schedule of Activities in 
Secti on 2 for the last participant. Study  completion is defined as the final date on which data for 
the primary endpo int is expected to be collected. Follow -up for a minimum of 3 years (from 
study  entry ) is planned, if applicable.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 47
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
 
 
6. STUDY POPULATION
For entry  into the study , the f ollowing criteria MUST be met.
6.1 Inclusion Criteria
1)Signed Written Informed Consent
a)Prior to study  participation, written informed consent from participant s, or in the case of 
minors, written permissio n (informed consent) from parents (both, if requi red by local 
law), guardi ans, or l egally acceptable representatives must be obtained according to l ocal 
laws and regulations.
b)Assent from minor participant s shoul d be obtained per local laws and regul ations and 
shoul d be docum ented in accordance wi th local requi rements.
c)Writteninformed consent and HIPAA authori zation (applies to covered entities in the 
USA only) obtained from the participant /legal representative prior to performing any 
protocol -related procedures, including screening evaluat ions
d)Participants must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory  testing, and other requi rements of the study , including disease assessment by 
contrast enhanced MRI.
2)Type of Participant and Target Disease Characteristics
a)Parti cipants must have received standard of care therapy , and there must be no 
potenti ally-curative treatm ent available, in one of the fo llowing Cohorts :
i)A newly diagnosed DIPG that has been treated with radiation therapy (RT) but no 
chemothe rapy. Diagnosi s of DIPG must be confirmed ei ther based on MRI criteria or 
histol ogy. (Cohort 1)
(1).Eligibilit y includes diffuse midline glioma wit h demo nstrated H3K27M mutation
(2).Biopsy  is not required for DIPG
(3).Enrollment can occur during radiat ion therapy  or up to 4 weeks after end of RT
ii)A histol ogically confi rmed recurrent or progressive non-brainstem HGG previ ously
treated with surgical resect ion and RT(with or wi thout chem otherapy ). (Cohort 2)
iii)Ahistol ogically  confirmed medull oblastom a thathas relapsed or isresistant to at least 
one line of prior therapy including surgery , RT, and chemotherapy (regardless of 
age). (Cohort 3)
iv)Ahistol ogically confi rmed ependymo ma thathas relapsed orisresistant to at least 
one line of prior therapy includ ingsurgical resect ion and RT(regardless of age).
(Cohort 4)
v)Ahistol ogically -confirmed high grade CNS malignancy “other than above” which is 
recurrent or progressive after at l east one line of prior therapy , including for exam ple: 
choroi d plexus carcino ma, germ  cell tumor, anaplast ic pleomorphic 
xanthoastrocy toma, pineoblastom a, AT/RT,embry onal tumor with multilayered 
rosettes (ETMR; C19MC -altered) that has relapsed or is resistant to at least one line 
of prior therap y. (Cohort 5) 
Revised Protocol No.: 01
Date: 11-Sep-2017 52
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
b)An interval of at least 12weeks after the end of prior radiati on therapy  is requi red unless 
there is either: i)histopathologic confirmat ion of recurrent tum or, or ii) new enhancement  
on MRI outside of the radiotherapy  treatm ent field ( applies only to Cohorts 2 -5).
c)Lansky play score (LPS) for 16 years of age or Karnofsky  perf ormance scale (KPS) for 
> 16 years of age assessed within two weeks of enrollment must be 60. Participant s 
who are unable to walk because of neurol ogic deficits, but who are up in a wheelchair, 
will be considered ambulatory  for the purpose of assessing the performance score 
(Appendix 6)
d)A tumor sample must be available for submissio n to central laboratory [not required for 
DIPG (Cohort 1)] . 
i)If surgery  was performed at time of recurrence, prior to study entry , a tumor sample 
from this resect ion shoul d be submitted. 
ii)If no re-operati on was perform ed, archival tumor from the most recent previous
resection should be su bmitted.
iii)Tumor sam ple must be su bmitted wi thin 30 days after treatm ent assi gnment
iv)Either a formalin-fixed, paraffin -embedded (FFPE) tissue block or unstained tumor 
tissue sections (recent: cut within 3 months), with an associ ated pathology report,
must be submi tted f or inclusio n.
e)Substant ialrecovery (ie, no ongoing safety issues) from surgical resecti on prior to first 
dose of study  therapy .
f)Revised as per Revised Protocol 02. Please refer to criterion 2j : An interval of 4 weeks 
(or 5 half- lives of a targeted therapies w ith short half -life) after the last administration of 
any other treatment for CNS malignancies (6 weeks for nitrosoureas). The interval from 
most recent bevacizumab must be 5 w eeks. The interval from most recent biological agent 
must be 7days or 5 half -lives, w hichever is longer.
g)Able to taper steroi ds, preferably discont inue. Parti cipants must be receiving not more 
than 0.05 mg/kg dexamethasone per day (or equivalent) for intracranial mass effect at 
study  entry .
h)Parti cipants who have received high-dose chemotherapy with autologous hematopoiet ic 
cell transplantati on must be at least 6 months post-hematopoiet ic cell transplantati on and 
they must h ave a CD4 count of at least 200.
i)Parti cipant re-enrollment: This study  permit s the re-enrollm ent of a partici pant that has 
discontinued the study as a pre-treatment failure (ie, participant has not been treated). If 
re-enrolled, the participant must be re -consented.
j)A minimum interval of 21 days after any prior therapy , including chemotherapy  or 
biolo gic agents, and at least 48 hours after any  intrathecal therapy. Caut ion should be 
used for blood counts recovery  after pri or alkylatingagent and for possible rebound 
edem a after pri or bevacizumab; in such cases, a longer int erval may  be needed.
3)Age a nd Reproductive Status
a)Males and Females, ages 6 months to < 22 years old at the time o f enrollment
Revised Protocol No.: 01
Date: 11-Sep-2017 53
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
b)Women of childbearing potential  (WOCBP) must have a negat ive serum  or urine 
pregnancy test (minimum sensi tivity 25 IU/L or equivalent units of human chori onic 
gonadotropin [ HCG ]) within 24 hours pri or to the start of study  treatm ent.
c)Women must not be breast feeding
d)WOCBP must agree to follow instructions for method(s) of contraception for the duration 
of study treatment with nivolumab and 5 months after the last dose of study treatment 
[ie,30 days (durati on of ovulatory  cycle) plus the time requi red for the investigational 
drug to undergo approximately five half -lives.]
e)Males who are sexually active with WOCBP must agree to follow instructi ons for 
meth od(s) of contracepti on for the duration of study treatm ent with nivolumab and 
7months after the last dose of study treatm ent [ie, 90 days (durati on of sperm turnover) 
plus the time required for the investigational drug to undergo approximately  5half-lives.]
f)Azoospermic males are exempt from contraceptive requi rements. WOCBP who are 
continuously not heterosexually active are also exem pt from contraceptive requi rements, 
butstill must undergo pregnancy testing as described in this section. 
Invest igators shall counsel WOCBP, and male participants who are sexually active with 
WOCBP, on the importance of pregnancy prevent ion and the implications of an unexpected 
pregnancy. At a minimum, contraceptive counseling shoul d be provi ded at the time ofassent or 
consent. Invest igators shall advise on the use of highly effect ive methods of contracepti on, 
(Appendix 4) which have a failure rate of < 1% when used consistent ly and correctly.
6.2 Exclusion Criteria
1)Medical Conditions
a)Parti cipants with an active, known ,or suspected autoimmune disease. Parti cipants with 
type I diabetes mellitus, hypothy roidism  only requiring horm one replacement, skin 
disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatm ent, or 
condi tions not expected torecur in the absence of an external trigger are permitted to 
enroll.
b)Parti cipants with a concurrent condit ion requiring systemic treatm ent with either 
corticosteroi ds (>0.25 mg/kg daily prednisone equivalent )or other immunosuppressive 
medicat ions within 14days of start of study treatment . Inhaled or topical steroids, and 
adrenal replacement steroi d doses > 0.25 mg/kg daily predniso ne equivalent , are 
permitted in the absence of act ive autoimmune disease.
c)Known history  of positive test for human immunodeficiency virus (HIV) or known 
acqui red immunodeficiency syndro me (AIDS). NOTE: Testing for HIV must be 
perform ed at si tes where m andated l ocally.
d)Any seri ous or uncontrolled medical disorder that, in the opini on of the invest igator, m ay 
increase the risk associ ated with study  participati on or study drug administration, impair 
the abilit y of the participant to receive protocol  therapy, or interfere with the 
interpretati on of  study  resul ts.
e)Parti cipants who cannot undergo magnetic resonance imaging (MRI)with contrast 
enhancement .
Revised Protocol No.: 01
Date: 11-Sep-2017 54
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
2)Target Disease Exclusion s
a)Unable to taper steroi ds due to ongoing mass effect; a maximum dexamethasone dose of 
0.05 m g/kg/day  is allowed, but preferably have been discont inued. 
b)Parti cipants with low-grade gliomas or tumors of unknown malignant potential are not 
eligible
c)Evidence of > Grade 1 recent CNS hemorrhage on the baseline MRI scan.
d)Parti cipants with bulky  tumor on imaging are ineligible; bulky tumor is defined as:
i)Tumor wi th any evidence of uncal herniat ion or severe midline shift
ii)Tumor wi th diameter of > 6cm in one dimensio n on T1 contrast -enhanced MRI
iii)Tumor th at in the opinio n of the invest igator, shows significant mass effect. (Contact 
BMS m edical m onitor forquestions .)
3)Prior/Concomitant Therapy
a)Prior treatment wi th an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA -4 antibody, or 
any other antibody  or drug specifically targeting T-cell co-stimulat ion or checkpo int 
pathways.
b)Prior all ogeneic hematopoi etic cell transplantati onunless MM approval in advance .
c)Participants who are receiving any other anti-cancer or invest igational drug therapy  or 
non-palliat ive radiat ion therapy  are ineligible .
4) Physical and Laboratory Test Findings
a)WBC < 2000/μL
b)Neutrophils < 1 000/μL
c)Platelets < 75x 103/μL(or transfusio n-dependent)
d)Hem oglobin < 9.0 g/dL (can be transfused)
e)Serum  creatinine > 1.5 xupper limit of normal based on age/gender as fo llows:
Table 6.2-1: Age/Gender Serum Creatinine Limits
Age Maximum Serum Creatinine (mg/dL)
Male Female
mg/dL umol/L (SI) mg/dL umol/L (SI)
1 to < 2 years 0.6 53 0.6 53
2 to < 6 years 0.8 71 0.8 71
6 to < 10 years 1 88 1 88
10 to < 13 years 1.2 106 1.2 106
13 to < 16 years 1.5 133 1.4 124
16 years 1.7 150 1.4 124
Note: the threshold values in this table were derived from the Schwartz formula for estimating GFR,60utilizing 
child length and stature data published by the US Centers for Disease Control and Prevention .
Revised Protocol No.: 01
Date: 11-Sep-2017 55
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
f)AST /ALT : > 3.0 x ULN . For the purposes of this tri al, a fixed ULN = 45 will  be used for 
AST and ALT.
g)Total  bilirubin > 1.5 x ULN (except parti cipants wi th Gilbert Syndrome who m ust have a 
total bilirubin level of < 3.0 x ULN) .
h)Any positive test result for hepatitis B virus or hepatit is C virus indicat ing presence of 
virus, eg,Hepati tis B surface antigen (HBsAg , Australia antigen) positive, or Hepatit is C 
antibody  (anti-HCV) posi tive (except if HCV -RNA negat ive).
5)Allergies and Adverse Drug Reaction
a)History  of allergy  or hy persensi tivity to study  drug com ponents
b)History  of severe hypersensit ivity react ion to any  monoclonal antibody .
6)Other Exclusion Criteria
a)Prisoners or participant s who are involuntarily incarcerated. (Note: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to 
continue as a participant . Strict condi tions apply and Bristol -Myers Squibb approval is 
requi red.
b)Parti cipants who are compulsorily  detained for treatm ent of either a psychiatric or 
physical ( eg, infect ious disease) illness .
Eligibilit y criteria for this study  have been carefully considered toensure the safety  of the study 
participant s and that the resul ts of the study  can be used. It is imperative that participant s fully 
meet all eligibilit y criteria.
6.3 Lifestyle Restrictions
Not applicable. No restrict ions are required.
6.4 Screen Failures
Screen failures are defined as parti cipants who consent to parti cipate in the clinical study  but are 
not subsequent ly entered into study treatm ent (second IRT visit entry ). A minimal set of screen 
failure informat ion is requi red to ensure transparent repor ting of screen failure participants, to 
meet the Conso lidated Standards of Reporting Trials (CONSORT) publishing requi rements, and 
to respond to queries from regulatory  authori ties. Minimal inform ation includes date of  consent, 
demography , screen failure d etails, eligibilit y criteria, and any  serious AEs.
6.4.1 Retesting During Screening or Lead -In Period
Parti cipant Re-enrollment: This study  permits the re-enrollment of a participant that has 
discontinued the study  as a pre-treatm ent failure (ie, participant hasnot been rando mized / has 
not been treated). If re -enrolled, the participant must be re -consented .
Retesting of laboratory  parameters and/or other assessments within any single Screening or 
Lead -in periodwill be permitted (in addition to any parameters that require a confirmatory 
value).
Revised Protocol No.: 01
Date: 11-Sep-2017 56
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
The most current result prior to first dose of study treatment is the value by which study 
inclusio n will  be assessed, as i t represents the participant ’s most current, clinical state.
Laboratory  parameters and/or assessme nts that are included in Table 2.-1, Screening Procedural 
Outline may be repeated in an effort to find all possible well-qualified participant s. Consultatio n 
with the Medi cal Monitor may be needed to identify whether repeat testing of any particular 
param eter is clinically relevant.
7. TREATMENT
Study  treatment is defined as any invest igational treatment(s), marketed product(s), placebo or 
medical device intended to be administered to a study participant according to the study 
treatm ent allocation.
Study  treatment includes both Invest igational [Medicinal] Product (IP/IMP) and 
Non-invest igational [Medicinal] Product (Non -IP/Non -IMP) and can consist of the fo llowing:
Nivo lumab
Ipilimumab
An invest igational product, also known as invest igational medicinal product in some regions, is 
defined a pharmaceut ical form of an active substance or placebo being tested or used as a 
reference in a clinical study , including products already with a marketing authori zation but used 
or assembled (form ulated or packaged) differently than the authorized form, or used for an 
unauthori zed indication, or when used to gain further information about the authori zed form .
In this protocol , nivolumab and ipilimumab are investigational products. Radiotherapy (prior to 
treatm ent start in Cohort 1) is not an invest igational product, even if given after enrollment.
Other medicat ions used as support or escape medicat ion for preventative, diagnost ic, or 
therapeuti c reasons, as components of the standard of care for a given diagnosis, may be 
considered a s non -invest igational products.
Revised Protocol No.: 01
Date: 11-Sep-2017 57
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 7. -1: Study treatment s for CA209908
Product 
Description / 
Class and 
Dosage FormPotency IP/Non -IMPBlinded or 
Open LabelPackaging / 
AppearanceStorage 
Conditions
(per label)
Nivolumab
Solution for 
Injectiona100 mg 
(10 mg/mL)IP Open label10 mL Vial (5 or 10 
vials /carton)
Clear to opalescent 
colorless to pale yellow 
liquid. May contain 
particles.Store at 2 to 8C. 
Protect from light 
and f reezing
Ipilimumab 
Solution for 
Injection200 mg
(5 mg/mL)IP Open -label40  mL vial (4 vials per 
carton)
Clear to opalescent 
colorless to pale yellow 
liquid. May contain 
particlesStore at 2 to 8°C. 
Protect from light 
and f reezing.
aNivolumab is labeled as BMS -936558- 01 Solution for Injection
7.1 Treatments Administered
Dosing calculati ons shoul d be based on the actual body  weight assessed at baseline. It is not 
necessary  to recal culate subsequent doses if the participant weight is within 10% of the weight 
used to cal culate the previous dose. All doses shoul dbe rounded up to the nearest milligram per 
institutional standard.
Parti cipants shoul d be carefully  monitored for infusio n react ions during nivolumab 
administration. If an acute infusio n react ion is noted, participants shoul d be managed according 
to Secti on 7.4.3 .
Doses of nivolumab may be interrupted during infusio n (see Section 7.4.3 ), delayed (see 
Secti on7.4.1 ), or discontinued (see Section 8.1)depending on how the participant tolerates 
treatm ent. Dosing visi ts (cycles) are not ski pped or omi tted, but they  may bedelayed. There will 
be no dose escalat ions or reductions of nivolumab allowed. Prem edicat ions are not 
recommended for the first dose of nivolumab. Nivo lumab and ipilimumab may be administered 
within 3 days before or after the scheduled dose. 
Nivo lumab Inject ion, 100 mg/10 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) nivolumab 
inject ion is to be administered as an IV infusio n through a 0.2-micron to 1.2-micron pore size, 
low-protein binding in -line filter at the protocol -specified doses. It is not to be administered as an 
IV push or bolus inject ion; any programmable infusion pump may be used. Nivolumab inject ion 
can be infused undiluted (10 mg/mL) or diluted with 0.9% Sodium Chloride Inject ion, USP or 
5% Dextrose Injection, USP to protein concentrati ons as low as 0.35 mg/mL. Instructions for 
dilution and infusio n of nivolumab inject ion may be provided in the clinical protocol , or 
Revised Protocol No.: 01
Date: 11-Sep-2017 58
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
pharmacy binder. Care must be taken to assure sterilit y of the prepared solution as the product 
does not contain any ant imicrobial preservat ive or bacteriostatic agent. 
Nivo lumab infusio ns are compatible with polyvinyl chloride (PVC) or polyo lefin containers and 
infusio n sets, and glass bottles.
Ipilimumab inject ion can be used for IV administrati on with or without dilut ion after transferring 
to a PVC, non-PVC/non -DEHP or glass container and is stable for 24 hours at 2-8°C or room 
temperature/room  light (RT/RL). For ipilimumab preparati on and storage instructions, refer to 
ipilimumab IB and Secti on 7.1.2 .
When study  drugs (nivo lumab and ipilimumab) are to be administered on the same day, 
nivolumab is to be administered first. Nivolumab infusio n must be prompt ly followed by  a saline 
flush or D5W flush to clear the line of nivoluma b before starting the ipilimumab infusio n. The 
second infusio n will always be the ipilimumab study  drug and will start after the infusion line 
has been flushed, filters changed, and participant has been observed to ensure no infusio n 
reacti on has occurred. The tim e in between infusio ns is expected to be approximately 30 minutes 
but m ay be m ore or l ess depending on the situation.
Separate i nfusi on bags and filters shoul d be used when administering nivolumab and ipilimuma b 
on the same day .
Care must be taken to assure sterilit y of the prepared solutions, since the drug product does not 
contain any antimicrobial preservat ives or bacteriostatic agents. At the end of the infusio n, flush 
the line wit h a sufficient quantit y of normal  saline or 5% dextrose solution.
This study  consists of 2 modules:
7.1.1 Module A (Nivolumab Monotherapy):
Parti cipants in Modul e A will receive nivolumab at a dose of 3 mg/kg as a 30-minute IV 
infusio n, on Day 1 of each treatm ent cycle every  2  w eeks. Participants shoul d begin study 
treatm ent within 3calendar days of treatm ent assignment (ie, second IRT visit entry ). 
Parti cipants in Cohort 1 will begin treatment within 6 weeks after the end of RT.
The select ion and timing of dose for each participant is as fo llows:
Table 7.1.1 -1: Selection and Timing of Dose forModule A (Nivolumab 
Monotherapy)
Study Treatment Unit dose 
strength(s)/Dosage 
level(s)Dosage formulation
Frequency of 
AdministrationRoute of Administration
Nivolumab 3 mg/kg Every 2 weeks IV
Revised Protocol No.: 01
Date: 11-Sep-2017 59
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
7.1.2 Module B (Nivolumab 3 mg /kg+ Ipilimumab 1 mg /kgCombination):
First 4 Cycles:
Parti cipants shoul d receive nivolumab at a dose of 3 m g/kg as a 30 -minute IV infusio n, followed 
30 minutes after by ipilimumab at a dose of 1 mg/kg as a 30 minutes IV infusio n on Day 1 of 
each treatm ent cycle every  3  w eeks, for 4 doses, until progressi on, unacceptable toxici ty, 
withdrawal  of consent, or the study  ends, whichever occurs first. Participants shoul d begin study 
treatm ent within 3calendar days of treatm ent assignment (ie, second IRT visit entry ). 
Parti cipants in Cohort 1 will begin treatment within 6 weeks after the end o f RT.
When study  drugs (nivo lumab and ipilimumab) are to be administered on the same day, 
nivoluma b is to be administered first. Nivo lumab infusio n must be prom ptly followed by a 
norm al saline or D5W flush to clear the line of nivolumab before starting theipilimumab 
infusio n. The second infusio n will always be the ipilimumab study  drug and will start after the 
infusio n line has been flushed, filters changed and participant has been observed to ensure no 
infusio n react ion has occurred. The time in between infusi ons is expected to be approximately 
30minutes but may be more or less depending on the situat ion.
Ipilimumab is to be administered as a 30 minute IV infusio n, using a volumetric pump with a 
0.2to 1.2 micron in-line filter at the protocol -specified dose. The drug can be diluted with 0.9% 
norm al saline or 5% Dextrose Injection to concentrati ons between 1 mg/mL and 4 mg/mL. It is 
not to be administered as an IV push or bol us injections. Care must be taken to assure sterili ty of 
the prepared sol utions, since the drug product does not con tain any ant imicrobial preservat ives or 
bacteri ostati c agents. At the end of the infusio n, flush the line with a  sufficient quant ity of 
norm al saline or 5% dextrose solution.
The select ion and timing of dose for each parti cipant is as fo llows:
Table 7.1.2-1: Selection and Timing of Dose forModule B (Nivolumab and 
Ipilimumab Combination) -First 4 cycles
Study Treatment Unit dose 
strength(s)/Dosage 
level(s)Dosage formulation
Frequency of 
AdministrationRoute of Administration
Nivolumab 3 mg/kg Every 3 weeks IV
Ipilimumab 1 mg/kg Every 3 weeks IV
Cycle 5 and beyond:
Parti cipants shoul d receive nivolumab at a dose of 3 m g/kg as a 30 -minute IV infusio n, on Day  1 
of each treatm ent cy cle every  2 weeks, starting 3 weeks after the fourth dose of the combinat ion.
The select ion and timing of dose for each participant is as fo llows:
Revised Protocol No.: 01
Date: 11-Sep-2017 60
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 7.1.2 -2: Selection and Timing of Dose forModule B (Nivolumab and 
Ipilimumab Combination) - Cycle 5 and B eyond
Study Treatment Unit dose 
strength(s)/Dosage 
level(s)Dosage formulation
Frequency of 
AdministrationRoute of Administration
Nivolumab 3 mg/kg Every 2 weeks IV
7.2 Method of Treatment Assignment
This is an open -label study. All participants will be assigned to treatm entusing an Interactive 
Response Techno logy (IRT). Before the study is initiated, each user will receive log in 
inform ation and di rections on how to access the IRT.
The first call to IRT will  be made in order to enroll  a participant and shoul d be made as soon as 
possible after informed consent has been obtained. An ident ificat ion number will be assigned and 
shoul d be used in all subsequent communicat ions.
The second call to IRT will be made when eligibilit y has been established and the participant is 
ready  to begin study  treatm ent. Subsequent assignments of study  drug are al so managed via IRT.
7.3 Blinding
This is an open -label study; blinding procedures are not applicable.
7.4 Dosage Modification
Dose m odificat ions related to management of specific AEs are described further in Appendix 5.
7.4.1 Dose Delay Criteria
Prem edicat ions are not recommended for the first dose of nivo lumab.
Parti cipants shoul d be carefully  monitored for infusio n react ions during nivolumab 
administration. If an acute infusio n react ion is noted, participants shoul d be managed according 
to Section 9.2.9 .
Doses of nivolumab and ipilimumab may be interrupted, delayed, or discontinued depending on 
how well the participant tolerates the treatm ent. Dosing visits are not skipped, only delayed. 
Tumor assessments for all participant s shoul d continue as per protocol  even if dosing is delayed. 
During Module B (nivo lumab and ipilimumab combinat ion), both nivolumab and ipilimumab 
shoul d be delayed at the same time. There will be no dose escal ations or reducti ons of nivo lumab 
allowed.
For the purposes of this trial, a fixed ULN = 45 will be used for AST and ALT. 
Nivo lumab administration should be delayed for the fo llowing:
Grade 2 non -skin, drug- related adverse event, with the exception o f fatigue
Grade 2 drug -related creatinine, AST, ALT and/or Total Bilirubin abnormalit ies
Grade 3 skin, drug- related adverse event
Revised Protocol No.: 01
Date: 11-Sep-2017 61
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Grade 3 drug -related laboratory abnormali ty, with the following except ions: 
Grade 3 lymphopenia or asymptomat ic amylase or lipase does not require dose delay
Grade 3 AST, ALT, Total Bilirubin will require dose discont inuat ion (see 
Section9.2.7 )
Any AE, laboratory  abnorm ality, or intercurrent illness which, in the judgment of the 
investigator, warrants delaying the dose of study  medi cation.
Parti cipants who requi re del ay ofnivolumab should be re -evaluated weekly or more frequent ly if 
clinically indicated and resume nivo lumab dosing when re -treatm ent cri teria are m et.
7.4.2 Criteria to Resume Treatment
Parti cipants who require delay of nivolumab or ipilimumab shoul d be re-evaluate d weekly or 
more frequent ly if clinically indicated and resume nivolumab dosing when re-treatm ent criteria 
are met.
Parti cipants may resume treatm ent with study  drug when the drug-related AE(s) resol ve to 
Grade1 or baseline value, with the fo llowing exc eptions:
Parti cipants may  resume treatm ent in the presence of Grade 2 fat igue
Parti cipants who have not experi enced a Grade 3 drug -related skin AE may  resume treatm ent 
in the presence of Grade 2 skin toxicit y
For participants with Grade 2 AST, ALT, or TBIL I elevations, dosing may resume when 
laboratory  values return to baseline and managem ent with corticosteroi ds, if needed, is 
complete.
Parti cipants with combined Grade 2 AST/ALT AND TBILI values meet ing discont inuat ion 
param eters shoul d have treatm ent perm anent ly discontinued. 
Drug -related pulmo nary toxicity, diarrhea, or colitis must have resolved to baseline before 
treatm ent is resumed. Parti cipants with persistent Grade 1 pneumo nitis after completion of a 
steroi d taper over at least 1 month may be eligible for retreatment if discussed with and 
approved by  BMS Medical  Moni tor.
Parti cipants with drug-related endocrinopathies adequately  controlled with only physi ologic 
horm one replacement may resume treatm ent after consultation with the BMS Medi cal Moni tor.
Adrenal insufficiency requires discont inuat ion regardless of control with hormone replacement.
If nivolumab treatm ent is delayed for any reason, ipilimumab must also be delayed until the 
participant has appropriately recovered and is able to resum e the combinat ion treatm ent on the 
first day  of the subsequent cy cle.
7.4.3 Treatment of Related Infusion Reactions
Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, each 
is unlikely to be immunogenic and induce infusion or hype rsensi tivity reacti ons. However, if 
such a reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, 
pruri tus, arthralgias, hypotensio n, hypertensio n, bronchospasm, or other allergic- like reacti ons. 
All Grade 3 or 4 infusio n reactions shoul d be reported within 24 hours to the BMS Study 
Revised Protocol No.: 01
Date: 11-Sep-2017 62
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Medical Moni tor and reported as an SAE if it meets the criteria. Infusio n react ions shoul d be 
graded according to NCI CTCAE (Version 4) guidelines.
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines, as appropriate:
For Grade 1 symptoms : (mild react ion; infusio n interrupti on not indicated; intervent ion not 
indicated):
Remain at bedside and monitor participant until recovery  from symptom s. The following 
prophylact ic prem edicat ions are recommended for future infusio ns: diphenhydramine 50 mg 
(as pediatric equivalent per kgor weight based pediatri c equivalent , at invest igator 
discreti on) and/or acetaminophen/paracetamo l appropri ate for age/weight at least 30minutes 
before addit ional nivo lumab administrations.
For Grade 2 symptoms : (moderate reaction requi red therapy  or infusio n interruption but 
responds prom ptly to symptomat ic treatment (eg, antihistamines, non-steroi dal 
anti-inflammat ory drugs, narcotics, corticosteroids, bronchodilators, IV fluids); prophylact ic 
medicat ions indicated for 24hours):
Stop the nivolumab or ipilimumab infusio n, begin an IV infusio n of normal  saline, and treat 
the participant with diphenhydramine 50 mg IV (as pediatric equivalent per kgor weight 
based pediatric equivalent , at invest igator discretion ) and/or acetaminophen/paracetamo l 
appropriate for age/weight ; remain at bedside and monitor participant until resolution of 
symptoms. Corti costeroi d and/or bronchodilator therapy  may also be administered as 
appropriate. If the infusio n is interrupted, then restart the infusio n at 50% of the original 
infusio n rate when symptom s resolve; if no further com plicati ons ensue af ter 30 minutes, the 
rate may be increas ed to 100% of the original infusio n rate. Monitor participant closely. If 
symptoms recur, then no further nivo lumab or i pilimumab will be administered at that visit.
For future infusio ns, the following prophylacti c prem edicat ions are recommended: 
diphenhydramine 50 mg (or pediatric equivalent per kg, at investigator’s discret ion) and/or 
acetaminophen/paracetamo l appropri ate for age/weight shoul d be administered at least 30 
minutes before nivolumab infusio ns. If necessary , corticosteroi ds (up to 25 mg of 
hydrocortisone or equivalent) may  be used.
For Grade 3 or 4 symptoms : (severe reacti on, Grade 3: prol onged [i e, not rapi dly responsive to 
symptom atic medicat ion and/or brief interruptio n of infusio n]; recurrence of symptoms 
following initial improvement; hospitalizat ion indicated for other clinical sequelae (eg, renal 
impairment, pulmo nary infiltrates). Grade 4: Life-threatening; pressor or ventilatory  support 
indicated):
Immediately discont inue infusio n of nivolumab or ipilimumab. Begin an IV infusio n of 
normal saline and treat the participant as follows: Recommend bronchodilators, epinephrine 
0.2 to 1mg of a  1:1000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 
1:10,000 solution injected slowly  for IV administration, and/or diphenhydramine 50 mg IV 
(or pediatric equivalent per kg, at investigator’s discretion) with methylpredniso lone 100 mg 
Revised Protocol No.: 01
Date: 11-Sep-2017 63
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
IV (orweight -based equivalent), as needed. Participant should be monitored until the 
Invest igator i s comf ortabl e that the symptom s will not recur. Study drug will be permanent ly 
discontinued. Invest igators should follow their institutional guidelines for the treatm ent of 
anaphylaxis. Remain at bedside and monitor participant until recovery  of the symptom s.
In case of late-occurring hypersensit ivity sympt oms (eg, appearance of a l ocalized or generalized 
pruri tus within 1 week after treatm ent), symptomat ic treatment may be given (eg, oral 
antihistamine or corticosteroi ds).
7.5 Preparation/Handling/Storage/Accountability
The invest igational product shoul d be stored in a secure area according to local regulat ions. It is 
the responsibilit y of the investigator to ensure that invest igational product is only dispensed to 
study  part icipants. The investigational product must be dispensed only from official study  sites 
by authori zed personnel according to local regulat ions.
The product storage manager shoul d ensure that th e study  treatm entis stored in accordance with 
the environmental condi tions (temperature, light, and humidit y) as determined by BMS. If 
concerns regarding the qualit y or appearance of the study  treatm entarise, the study treatm ent
shoul d not be di spensed and contact BMS im mediately.
Study  treatm entnot supplied by BMS will be stored in accordance with the package insert.
Invest igational product documentation (whether supplied by BMS or not) must be maintained 
that includes all processes requi red to ensure drug is accurately administered. This includes 
docum entati on of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes ( eg, requi red diluents, administration sets).
For details on prepared drug storage and use time of nivolumab and ipilimumab under room 
temperature/light and refrigerat ion, please refer to the nivolumab IB47section for 
“Reco mmended Storage and Use Condit ions” and/or pharmacy manual.
Further gui dance and information for final disposit ion of unused study  treatment are provided 
in Appendix 2 and Study  Pharmacy Manual.
7.5.1 Retained Samples for Bioavailability / Bioequivalence
Not Applicable.
7.6 Treatment Compliance
Treatment compliance will be monitored by drug accountabilit y as well as by the participant’s 
medical record and Case Report Form (CRF).
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 64
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 65
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
 
 
 
 
7.8 Treatment After the End of the Study
At the concl usion of the study , participants who continue to demonstrate clinical benefit will be 
eligible to receive BMS supplied study  treatment. Study  treatment will be provi ded via an 
extensio n of the study , a rollo ver study  requiring approval by responsible healt h authori ty and 
ethics commi ttee or through another mechanism at the discretion of BMS.
BMS reserves the right to terminate access to BMS supplied study  treatm ent if any of the 
following occur: a) the study  is terminated due to safet y concerns; b)the development of the
nivolumab is terminated for other reasons, including but not limit ed to l ack of efficacy and/or not 
meet ing the study  object ives; c) the participant can obtain medication from a governme nt 
sponsored or private healt h program . In all cases BMS will fo llow local regulati ons.
8. DISCONTINUATION CRIT ERIA
Tumor assessments shoul d continue as per protocol even if dosing is delayed. Periodic study 
visits to assess safety and laboratory  studies shou ld also continue every  6weeks or more 
frequently if clinically indic ated during such dosing delays.
8.1 Discontinuation from Study Treatment
Parti cipants MUST discont inue invest igational product (and non-invest igational product at the 
discreti on of  the invest igator) for any o f the following reasons:
Confirmed radio logic disease progression or investigator -assessed clinical progressi on as 
described in Secti on 9.1.2
Toxicit y as specified below and in Section 9.2
Parti cipant’s request to stop study treatm ent. Participants who request to discontinue study 
treatm ent will remain in the study  and must continue to be followed for protocol specified 
follow-up procedures. The only  excepti on to this is when a parti cipant s pecifically wit hdraws 
Revised Protocol No.: 01
Date: 11-Sep-2017 66
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
consent for any further contact with him/her or persons previously authorized by partici pant 
to provi de this information (See Secti on 8.2)
Any clinical adverse event (AE), laboratory  abnormalit y or intercurrent illness which, in the 
opinio n of the invest igator, indicates that continued participat ion in the study  is not in the 
best interest of the participant .
Maximum clinical be nefit as assessed by Investigator
Pregnancy (as specified in Sect ion 9.2.5 )
Terminat ion of the study  by Bristol -Myers Squibb (BMS)
Loss of ability to freely provide consent through imprisonment or involuntarily incarceration 
for treatm ent of ei ther a psychiatric or physical (eg, infect ious di sease) illness
In the case of pregnancy , the investigator must immediately notify the Sponsor or designee of 
this event. In most cases, the study  drug will be permanent ly discontinued in an appropriate 
manner (eg, dose tapering if necessary for participant safet y). Please contact the Sponsor or 
designee wit hin 24 hours of awareness of the pregnancy. If the invest igator determines a possible 
favorable benefit/risk ratio that warrants continuation of study drug, a discussion between the 
investigator and the Sponsor or designee must occur.
Discontinuati on of the study  treatm ent for abnorm al liver tests should be consi dered by the 
investigator when a parti cipant meets one of the condi tions outlined (in the al gorithm below) OR 
(in Appendix 5) or if the invest igator believes that it is in best interest of the participant.
Refer to the Schedule of Activities for data to becollected at the time of treatment 
discontinuat ion and fo llow-up and for any  further evaluat ions that can be completed
All participants who discont inue study  treatment shoul d comply with protocol  specified follow-
up procedures as outlined in Secti on 2. The only except ion to this requi rement is when a 
participant withdraws consent for all study  procedures including post-treatm ent study  follow-up 
or loses the abilit y to consent freely (ie, is impri soned or involuntarily incarcerated for the 
treatm ent of ei ther a psy chiatri c or physical illness).
If study  treatment is discont inued prior to the participant’s completion of the study , the reason 
for the discont inuat ion must be docum ented in the participant’s medical records and reported
page.
8.1.1 Discontinuation of N ivolumab Due to Toxicity [Module A or B] 
For the purposes of this trial, a fixed ULN = 45 will be used for AST and ALT.
Nivo lumab treatment should be permanent ly discont inued for the fo llowing:
Any Grade 2 drug-related uveit is, eye pain or blurred visio n that does not respond to topi cal 
therapy  and does not improve to Grade 1 severi ty within the re -treatm ent peri od OR requi res 
systemic treatment
Revised Protocol No.: 01
Date: 11-Sep-2017 67
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Any Grade 3 non- skin, drug-related adverse event lasting > 7 days or recurs, with the 
following except ions for laboratory  abnorm alities, drug-related uveit is, pneumo nitis, 
bronchospasm, neuro logic toxicity,hypersensitivit y react ions, infusio n reacti ons, and 
endocrinopathies :
Grade 3 drug-related uveit is, pneumo nitis, bronchospasm, neuro logic toxicity,
hypersensi tivity reaction, myocardi tis or infusion reaction of any durati on requi res 
discontinuat ion
Grade 3 drug-related endocrinopathies, adequately controlled with only phys iologic 
horm one replacement do not require discontinuati on. Adrenal insufficiency requires 
discontinuat ion regardless o f control  with hormone repl acement.
Grade 3 drug-related laboratory  abnorm alities do not require treatm ent discont inuat ion 
except:
Grade 3 drug-related thrombocy topeni a > 7 days or associ ated with bleeding 
requi res discont inuat ion
Grade 3 drug -related AST, ALT or Total Bilirubin requires discont inuat ion*
Concurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN (see 
Secti on9.2.7 )
Any Grade 4 drug-related adverse event or laboratory  abnorm ality (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the following events which do not 
requi re discontinuati on:
Grade 4 neutropenia 7 days
Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase
Isolated Grade 4 el ectroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corre cted with supplementati on/appropri ate management within 
72hours of their onset
Grade 4 drug-related endocrinopathy  adverse events, such as, hyper -or hypothy roidism, 
or glucose intolerance, which resolve or are adequately controlled with physio logic 
horm one replacement (corti costeroi ds, thyroid horm ones) or glucose -controlling agents, 
respectively , may not requi re discontinuat ion after di scussio n with and approval  from the 
BMS Medical Monitor.
Any event that l eads to delay  in dosing l asting >6 weeks for n ivolumab monotherapy  from 
the previous dose requires discont inuat ion, wi th the fo llowing except ions:
Dosing delays to allow for prolonged steroi d tapers to manage drug-related adverse 
events are allowed. 
Dosing delays lasting > 6 weeks from the previo us dose that occur for non-drug-related 
reasons may  be allowed if approved by  the BMS medical m onitor.
Prior to re-initiating treatm ent in a participant with a dosing delay lasting > 6 weeks, the BMS 
medical mo nitor must be consulted.
* In most cases of Grade 3 AST or ALT elevat ion, study  drug(s) will be perm anent ly 
discontinued. If the invest igator determines a possible favorable benefit/risk ratio that warrants 
continuat ion of study drug(s), a discussio n between the invest igator and the BMS Medical 
Moni tor/desi gnee m ust occur.
Revised Protocol No.: 01
Date: 11-Sep-2017 68
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
8.1.2 Discontinuation of Combina tion treatment due to Toxicity [ Module B ]
Addit ional criteria apply  to participants in Module B; the criteria above for nivolumab apply to 
both Modul es. To the extent possible , assessment for discontinuat ion of nivolumab shoul d be 
made separately  from the assessment made for discontinuat ion of ipilimumab. Although there is 
overl ap among the discont inuat ion criteria, if discontinuat ion criteria are met for ipilimumab but 
not for nivolumab, treatm ent with nivolumab may continue if ipilimumab is discontinued. After 
discussio n with the Medi cal Monitor, nivolumab monotherapy  may continue if ipilimumab is 
discontinued. If a participant in Module B meets criteria for discont inuat ion and invest igator is
unable to d etermine whether the event is rel ated to both or one study  drug, the parti cipant should 
discontinue both nivolumab and ipilimumab ,and be taken off the treatm ent phase of the study .
At invest igator discret ion, with approval  of BMS medical monitor, participant may discont inue 
ipilimumab and (after recovery  of AEs) m ay restart nivol umab m onotherapy .
Nivo lumab and Ipilimumab treatment should be permanently discontinued for the following:
Any Grade 2 drug-related uveit is, eye pain or blurred visio n thatdoes not respond to topi cal 
therapy  and does not improve to Grade 1 severi ty within the re -treatm ent peri od OR requi res 
systemic treatment 
Any Grade 3 non- skin, drug-related adverse event lasting > 7 days, or recurs with the 
following except ions for labo ratory  abnorm alities, di arrhea, coli tis, neurol ogic toxici ty, drug -
related uveit is, pneumonit is, bronchospasm, hypersensit ivity react ions, infusio n reacti ons, 
and endocrinopathies:
Grade 3 drug-related diarrhea, colitis, neurologic toxicity, uveitis, pneum onitis, 
bronchospasm, hypersensit ivity react ion, myocardi tis, orinfusio n react ion of any 
durati on requi res discont inuat ion
Grade 3 drug-related endocrinopath ies, adequately controlled with only physi ologic 
horm one replacement do not require discontinuati on. Adrenal insufficiency requires 
discontinuat ion regardless o f control  with hormone repl acement. 
Grade 3 drug-related laboratory  abnorm alities do not require treatm ent discont inuat ion 
except:
Grade 3 drug-related thrombocy topeni a > 7 days or associ ated with bleeding 
requi res discont inuat ion
Any drug-related liver function test (LFT) abnormalit y that meets the following 
criteria requi re discontinuati on:
oGrade 3 drug -related AST, ALT or Total Bilirubin requires discont inuat ion*
oConcurrent AST or ALT > 3 x ULN and total bilirubin > 2x ULN
* In most cases of Grade 3 AST or ALT elevat ion, study  drug(s) will be perm anent ly 
discontinued. If the invest igator determines a possible favorable benefit/risk ratio that warrants 
continuat ion of study drug(s), a discus sion between the invest igator and the BMS Medical 
Moni tor/desi gnee m ust occur.
Revised Protocol No.: 01
Date: 11-Sep-2017 69
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Any Grade 4 drug-related adverse event or laboratory  abnorm ality (including but not limited 
to creatinine, AST, ALT, or Total Bilirubin), except for the following events which do not 
requi re discontinuati on:
Grade 4 neutropenia 7 days
Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase
Isolated Grade 4 el ectroly te imbalances/abnormalities that are not associated with clinical 
sequelae and are corrected with supp lementati on/appropri ate management within 
72hours of their onset
Grade 4 drug-related endocrinopathy: adverse events, such as, hyper -or hypothyro idism, 
or glucose intolerance, which resolve or are adequately controlled with physio logic 
horm one replacement (corti costeroi ds, thyroid horm ones) or glucose -controlling agents, 
respectively , may not requi re dis continuat ion after di scussio n with and approval  from the 
BMS Medical Monitor.
Any event that leads to delay  in dosing during combinat ion therapy  lasting > 8 weeks 
(Modul e B) f rom the previ ous dose requi res discontinuat ion, wi th the fo llowing except ions:
Dosing delays to allow for prolonged steroi d tapers to manage drug-related adverse 
events are allowed. 
Dosing delays lasting > 8 weeks for combinat ion therapy  from the previous dose that 
occur for non-drug-related reasons may be allowed if approved by the BMS medical 
monitor.
Prior to re-initiating treatm ent in a participant with a dosing delay lasting > 6 weeks, the BMS 
medical mo nitor must be consulted. 
8.1.3 Post Study Drug Study Follow -up
For follow -up of  AEs and SAEs after discont inuat ion of study  treatm ent,see Section 9.2.
OS and PFS are key endpoint sof thisstudy . Post study  follow-up is of critical importance and is 
essent ial to preserving participant safet y and the integrity of the study . Parti cipants who 
discontinue study  treatment must continue to be followed for collect ion of progression and/or 
survival informat ion according to Section 5.1.5 , ie, until disease progressi on and at least 3 years 
for survival (as applicable). 
BMS may request that survival data be collected on all treated participants outsi de of the 
protocol  defined window (Table 2.-1, Table 2.-2, Table 2.-3, andTable 2.-4). At the time of this 
request, each participant will be contacted to determine their survival status unless the participant 
has wi thdrawn consent for all contacts or is lost to fo llow-up.
8.2 Discontinuation from the Study
Parti cipants who request to discont inue study  treatm entwill remain in the study  and must 
continue to be followed for protocol  specified follow-up procedures. The only excepti on to thi s 
is when a participant specifically withdraws consent for any further contact with him/her or 
persons previously authorized by partici pant to provide this information. 
Parti cipants shoul d notify  the investigator of the decisio n to withdraw consent from future 
follow-up in writing, whenever possible.
Revised Protocol No.: 01
Date: 11-Sep-2017 70
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
The withdrawal  of consent should be explained in detail in the medical records by the 
investigator, as to whether the withdrawal is from further treatment with study  treatm entonly 
or also from study  procedures and/or post treatment study  follow-up, and entered on the 
appropriate CRF page.
In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly  available informat ion shoul d be used to determine vital status only as appropri ately 
directed in accordance with local law.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may 
retain and cont inue to use any data collected befor e such a withdrawal o f consent.
Withdrawal of consent may be requested by participant s, parents, guardians, or legally 
accep table representatives, in accordance with local regulat ions. The wishes of minor 
participant s to withdraw their assent should also be respected.
8.3 Lost to Follow -Up
All reasonable efforts must be made to locate participant s to determine and report their 
ongoing status. This includes fo llow-up wi th persons authori zed by the participant .
Lost to follow -up is defined by  the inabili ty to reach the participant after a minimum  of three
docum ented phone calls, faxes, or emails as well as lack of response by participant to one 
registered mail letter. All attem pts shoul d be docum ented in the participant’s medical 
records.
If it is determined that the participant has died, the site will use permissible local methods to 
obtain date and cause of death.
If invest igator’s use of third-party  representative to assist in the follow-up portion of the 
study  has been included in the participant’s informed consent, then the investigator may  use a 
Sponsor retained third-party  representative to assist site staff with obtaining participant’s 
contact information or other public vital status data necessary to complete the follow-up 
porti on of  the study . 
The si te staff  and representative will consul t publicly available sources, such as public healt h 
registries and databases, in order to obta in updated contact information.
If after all attem pts, the participant remains lost to follow-up, then the last known alive date 
as determined by the investigator should be reported and docum ented in the participant’s 
medical rec ords.
9. STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and timing are summarized in the S chedule of Activities. 
Protocol  waivers or exempt ions are not allowed .
All immediate safet y concerns must bediscussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatm ent.
Adherence to the study  design requi rements, including those specified in the Schedule of 
Activities, is essenti al and requi red for study  conduct.
All screening evaluat ions must be completed and reviewed to confirm that potential 
participants m eet all eligibili ty criteria before treatment start . The invest igator will maintain a 
Revised Protocol No.: 01
Date: 11-Sep-2017 71
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
screening log to record details of all participants screened and to confi rm eligibili ty or recor d 
reasons for scr eening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of inform ed consent may be utilized for screening or 
baseline purposes provided the procedure meets the protocol -defined criteria and has been 
perform ed wi thin the timeframe defined in the Schedul e of Activities.
Addit ional measures, including non-study  required laboratory  tests, shoul d be performed as 
clinically indicated or to com ply with local regulati ons. Laboratory  toxicities (eg, suspected drug 
induced liver enzyme evaluat ions) will be monitored during the follow-up phase via on si te/local 
labs unt il all study drug related toxicit ies reso lve, return to baseline, or are deemed irreve rsible.
If a participant shows pulmo nary-related signs (hypoxia, tachypnea )or symptoms (eg. dyspnea, 
cough, fever) consistent with possible pulmo nary adverse events, the participant should be 
immediately evaluated to rule out pulmo nary toxicit y, according to the suspected pulmo nary 
toxicity management al gorithm Appendix 5 .47
Some of the assessments referred to in this section may not be captured as data in the eCRF. 
They  are intended to be used as safet y monitoring by the treating physician. Addit ional testing or
assessments may be perform ed as clinically  necessary  or wh ere required by institutional or local 
regul ations.
9.1 Efficacy Assessments
Efficacy will be based on imaging assessments (Secti on 9.1.1 ) suppl emented by clinical 
neuro logic examinat ion andperformance status as well  asadditional considerat ions as applicable 
eg,steroid requirement, CSF cytopathol ogy.Consensus Reco mmendat ions for imaging of brain
tumors61shoul d be followed. Addit ional sequences, based on the clinical setting, shoul d be 
included at the discret ion of the neuroradio logist.
Study  endpoints of response or progression will be based on widely -accepted RANO criteria 
(See Section 9.1.3 ); in pediatri c tumors, however, interpretation by an experi enced 
neuroradi ologist is essent ial. For tumors with a propensit y to disseminate in the leptomenin ges, 
guidance contained in paper entitled Response Assessment in Medullo blastoma and 
Leptom eningeal Seeding Tum ors: Recommendat ions from the Response Assessment in Pedi atric 
Neuro -Oncology Committee by Warren et al54should be considered, particularly with respect to 
imaging and cytopathol ogic parameters. The expectations stated in Schedule of Activities and 
Secti on 9.1.1 are generally applicable, but invest igators have discret ion to modify the frequency 
of spine MRI and CSF cy topathol ogy based on individual circumstances.
In addition, considerat ion may be given to the recent iRANO proposal .62As these proposed 
criteria have not y et been widely  applied ,they may be considered as an exploratory endpo int.
Revised Protocol No.: 01
Date: 11-Sep-2017 72
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
9.1.1 Imaging Assessment for the Study
All participant s will undergo contrast enhanced brain MRI at the time points specified in Table 
2.-1, Table 2.-2, Table 2.-3, andTable 2.-4. An Imaging Manual will be provi ded. Screening 
MRI may be perform ed prior to informed consent , as part of standard care. Adequate qualit y of 
the baseline evaluat ion must be assured by the PI prior to treatm ent start and repeat imaging 
perform ed if not adequate. However, i t is not necessary  that the MRI machine be “qualified” (by 
imaging CRO) for the screening evaluat ion. 
ForInclusio n of Cohorts 2- 5, if first recurrence of the CNS tumor is docum ented by MRI, an 
interval of at least 12 weeks after the end of prior radiat ion therapy is requi red unless there is 
either: i) histopathologic confirmat ion of recurrent tumor, or ii) new enhanc ing mass on MRI 
outsi de of  the radi otherapy  treatm ent field. 
Evaluat ion of the leptomenin gesis standard in many pediatri c CNS malignancies and shoul d be 
perform ed as clinically indicated. In Cohorts 3 and 5, a baseline MRI spine and CSF 
cytopath ology  are expected , unless clinically contraindicated. In Cohorts 2 and 4, baseline MRI 
spine and CSF cytopathol ogy may be obtained based on clinical judgment; theseare not 
expected in Cohort 1.
On treatm ent and follow up MRIs shoul d occur on the following schedule: Q6W x 2 
assessments, then Q8W x 4, and then Q12W (1 week ). The expected timing of tumor 
assessments is therefore at Weeks 7, 13, 21, 29, 37, 45, and subsequent ly every  12 weeks. 
Invest igators may obtain more frequent follow-up MRI scans as medically indicated. Local 
radiologic assessment of tumor measurements will be used during the study  for clinical 
management and invest igator -assessed disease progre ssion. MRI scans shoul d continue on the 
indicated schedule regardless of treatment de lay.
If baseline MRI spine showed metastati c deposits, then it should be repeated at the same 
intervals as the MRI of brain, ie regular tumor assessments indicated inTable 2.-2, Table 2.-3, 
and Table 2.-4, ordinarily at the same imaging sessio n. Frequ ency of MRI spine is at the 
investigator’s discret ion. If the baseline is negative, thenless frequent re-assessment may be 
appropriate depending on the individual circumstances. All imaging assessments of sites of 
disease shoul d be submi tted (Secti on5.1.6.3 ) to the central imaging laboratory .
If baseline CSF cytopathol ogy is positive, then it should be repeated approximately  every 
8weeks during study , as clinically indicated .
Parti cipants who are unable (due to exi stent medical condition, ie, pacemaker or ICD devi ce) or 
unwilling to have a contrast enhanced MRI of the brain at baseline are excluded from the study . 
Parti cipants who become unable to undergo MRI imaging after the start of participat ion in the 
study may continue in the study  for assessment of overall  survival as long as there is no safet y 
issue which would require mo nitoring by MRI.
Study -related MRI imaging of the brain will be perform ed per the frequency specified above . 
Invest igators may obtain additional MRI scans as medically indicated. For other locally 
perform ed imaging, it is the local imaging facilit y’s responsibilit y to determine, based on 
Revised Protocol No.: 01
Date: 11-Sep-2017 73
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
participant attributes (eg, allergy history , diabetic history , and renal status), the appropriate 
imaging modality, and contrast regimen for each participant . Imaging contraindications and 
contrast risks shoul d be considered in this assessment. Participant s with severe renal 
insufficiency (ie, estimat ed glomerular filtrat ion rate < 30 mL/min/1.73 m2) are at increased risk 
of nephrogenic systemic fibrosis. MRI contrast should not be given to this participant populat ion, 
who shoul d be excluded from the study . In addition, participant s with surgically implanted 
devices (pacemaker, deep brain stimulator, metallic implants, etc) incompat ible with MRI should 
not undergo such imaging techniques. The local imaging facilit y and invest igator shoul d 
determine the appropri ate precauti ons or gui delines that shoul d be instituted for participant s with 
tattoos, body piercings, or other body  art.
The ul timate deci sion to pe rform MRI in an individual participant in this study  rests wi th the site 
radiologist, the invest igator and the standard set by the local Ethics Commit tee. 
Study  sites will retain local access to the imaging resul ts for safet y and efficacy reading 
purposes. The study  investi gator will review the local MRI resul ts as clinically  appropri ate to 
ensure that any potenti ally emergent clinical situati ons are addressed in a timely fashio n. 
Clinically significant radiologic findings or changes from baseline scans will  be coded as AEs or 
SAEs according to the criteria described in Section 9.2. Any addit ional or incidental radiographic 
findings of potential  clinical relevance that are not direct ly associ ated with the object ives of the 
protocol  should be evaluated and handled by theStudy  Invest igator as per standard 
medical/clinical judgment.
Sites will be trained in image acquisit ion parameters, the submissi on process, and application of 
RANO cri teria63prior to scanning the first study participant . These gui delines will be outline d in 
a separate Si te Imaging Manual provi ded by the imaging core lab. Invest igators will assess PFS, 
ORR and DOR based on RANO criteria. 
All radiologic imaging from this study  will be transmitted to a centralized imaging core lab for 
storag e and sponsor a ccess . At Sponsor request , BICR willassess PFS in all Cohorts and ORR in 
participants with measurable disease .
9.1.2 Suspected Progression
In order to distinguish potenti al treatm ent effects (or “pseudo -progression”), from progressive 
disease and thus to minimi ze prem ature discont inuation of treatm ent, participant s who initially 
meet radiologic criteria for disease progressi on, but are tolerating study  drug, may continue 
receiving study  drug until  confi rmation of progressi on. If the follow-up assessment confirms that 
progression has occurred, the date of  progressi on will be the date at which progressi on was first 
determined. If the follow-up assessment does not confirm progressi on, then the original  time 
point response will be assessed as SD. If possible, MRI perfusio n images shoul d also be 
obtained. 
If a determi nation cannot be made after a 6 to 8 week interval, then treatm ent may  continue until 
either progressi on is confirmed or regressio n is observed, consistent with either 
Revised Protocol No.: 01
Date: 11-Sep-2017 74
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
pseudoprogression (in Cohort 1) or immune -treatm ent effect. There is no time limit for 
confirmat ion of progression. The BMS Medical Monitor should be consulted.
Suspected disease progressi on within 12 weeks after the end of RT must be confirmed (per 
RANO) by subsequent MRI perform ed approximately 6-8 weeks after the initial radiological 
assessment of progression. Prior to 12 weeks after RT, progression can only be defined using 
diagnosti c imaging if there is new enhancement outsi de of the radiat ion field (beyond the high-
dose region or 80% isodose line) or if there is unequivocal evidence of viable tumor on 
histopathologic sampling.63Note: in the absence of radiographic or histologic confi rmation of 
progression, clinical decline alo ne is not sufficient for definit ion of progressive disease.
9.1.3 Assessment of Response
Response will be assessed using RANO 2010 criteria.63Table 9.1.3 -1describes the radiological 
and clinical cri teria that will be used for determining tum or response. Table 9.1.3 -2describes the 
criteria used for assessing eligibili ty (for Cohorts 2-5), based on time from prior RT (See 
Secti on6.1). Table 9.1.3 -3describe s the criteria will be used for assessing BOR . All measurable 
and non -measurable lesio ns must be assessed using the same techniques as at baseline.
Parti cipants who have no lesion measuring 1 cm  on 2 perpendicular diameters on baseline MRI 
cannot have a complete or partial response and will be followed only for recurrence . Similarly, 
participants with DIPG in Cohort 1 (ie, in the post-RT period) will be considered to have non-
measureable disease. These participant s will be considered non-evaluable for BOR analysis, but 
their disease status will be assessed (SD or PD) at each tumor assessment, and they will be 
included in analysis of PFS and OS. If no signs of progressi on are observed byMRI, the 
radiologic assessment will be categorized as SD. The appearance of any new lesion consistent  
with tumor will be categorized as PD.
The assessments that will contribute to evaluat ion of PD include response assessments recorded 
between the date of first dose of study  therapy and the first to occur of the following:
1)The date of object ively documented progression per RANO criteria
2)The date of subsequent therapy , or
3)The date of pathology  resul ts from diagnost ic surgical resect ion
4)The date of clinical progres sion
The minimum durat ion between baseline scan and first on -study  scan in order to determine BOR 
of SD is at least 5weeks on study . If the minimum time is not m et when SD is otherwi se the best 
time point response, the participant ’s best response will depend on the subsequent assessments. 
For exam ple, a participant who has SD at a tim epoint < 6weeks and PD at a second assessment, 
will have a best response of PD.
Revised Protocol No.: 01
Date: 11-Sep-2017 75
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 9.1.3 -1: RANO Criteria for Time -point Response Assessment Inco rporating 
MRI and Clinical Factors
Response Criteria
CR Requires all of the following: complete disappearance of all enhancing measurable and 
nonmeasurable disea se;no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; 
participant s must be off corticosteroids (or on physiologic replacement doses only); and stable or 
improved clinically. Note: Participant s with nonmeasurable disease only cannot have a complete 
response; the best response possible is stable disease.
PR Requires all of the following: 50% decrease compared with baseline in the sum of products of 
perpendicular diameters of all measurable enhanci ng lesions ; no progression of nonmeasurable 
disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower 
dose of corticosteroids compared with baseline scan; the corticosteroid dose at the time of the 
scan evaluation should be no greater than the dose at time of baseline scan; and stable or 
improved clinically. Note: Participant s with nonmeasurable disease only cannot have a partial 
response; the best response possible is stable disease.
SD Requires all of the following: does not qualify for complete response, partial response, or 
progression; stable nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids 
compared with baseline scan. In the event that the corticosteroid dose was increased for new 
symptoms and signs without confirmation of disease progression on neuroimaging, and 
subsequent follow -up imaging shows that this increase in corticosteroids was required because of 
disease progression, the last scan considered to show stable disease will be the scan obtained 
when the corticosteroid dose was equivalent to the baseline dose.
PD Defined by any of the following: 25% increase in sum of the products of perpendicular 
diameters of enhancing lesions compared with the smallest tumor measurement obtained either at 
baseline (if no decrease) or best response, on stable or increasing doses of corticosteroids (Stable 
doses of corticosteroids include participant snot on corticosteroids); significant increase in 
T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with 
baseline scan or best response after initiation of therapy* not cause dby comorbid events (eg, 
radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or 
other treatment effects); any new lesion; clear clinical deterioration not attributable to other 
causes apart from the tumor (eg, seizure s, medication adverse effects, complications of therapy, 
cerebrovascular events, infection, and so on) or changes in corticosteroid dose; failure to return 
for evaluation as a result of death or deteriorating condition; or clear progression of 
nonmeasurabl e disease.
Revised Protocol No.: 01
Date: 11-Sep-2017 76
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Table 9.1.3 -2: Criteria for Determining First Progressio n Depending on Time 
after Radiotherapy 
First ProgressionDefinitiona
Progressive disease < 12
weeks after completion 
of radiotherapyProgression can only be defined using diagnostic imaging if there is new 
enhancement outside of the radiation field (beyond the high -dose region or 80% 
isodose line) or if there is unequivocal evidence of viable tumor or histopathologic 
sampling (eg, solid tumor areas [i e, > 70% tumor cell nuclei in areas], high or 
progressive increase in MIB -1 proliferation index compared with prior biopsy, or 
evidence for histologic progression or increased anaplasia in tumor). Note: Given the 
difficulty of differentiating true progress ion from pseudoprogression, clinical decline 
alone, in the absence of radiographic or histologic confirmation of progression, will 
not be sufficient for definition of progressive disease in the first 12 weeks after 
completion of radiotherapy.
Progressive disease 12 
weeks after completion
of radiotherapy1. New contrast -enhancing lesion outside of radiation field on decreasing, stable, or 
increasing doses of corticosteroids.
2. Increase by 25% in the sum of the products of perpendicular diameters betwee n 
the first post radiotherapy scan, or a subsequent scan with smaller tumor size, and the 
scan at 12 weeks or later on stable or increasing doses of corticosteroids.
3. Clinical deterioration not attributable to concurrent medication or comorbid 
conditio nsis sufficient to declare progression on current treatment but not for entry 
onto a clinical trial for recurrence.
4. For participant s receiving antiangiogenic therapy, significant increase in T2/FLAIR 
non-enhancing lesion may also be considered progressiv e disease. The increased 
T2/FLAIR must have occurred with the participant on stable or increasing doses of 
corticosteroids compared with baseline scan or best response after initiation of 
therapy  and not be a result of comorbid events (e g, effects of radia tion therapy , 
demy elinatio n, ischemic injury, infection, seizures, postoperative changes, or other 
treatment effects).
aWen PY, Macdonald DR, Reardon DA, et al. Updated Response Assessment Criteria for High-Grade Gliomas: 
Response Assessment in Neuro -Oncology Working Group; J Clin Oncol. 2010 Apr 10; 28(11):1963 -72.
Table 9.1.3 -3: Asse ssment of Best Overall Response
Best Overall ResponseCriteriaa
CR CR observed in assessments 4 weeks apart per RANO
PR PR observed in assessments 4 weeks apart per RANO
SD 
Note: To qualify for SD there 
must be a minimum on -
treatment period of 6 weeks.)SD observed and does not qualify for CR or PR 
or 
Suspected PD followed with histologic results not confirming PD, and no CR, 
PR or SD observed 
Not Evaluable (NE) Insufficient data to determine disease progression or response
PD No CR, PR, or SD prior to PD
aWen PY, Macdonald DR, Reardon DA, et al. Updated Response Assessment Criteria for High-Grade Gliomas: 
Response Assessment in Neuro -Oncology Working Group; J Clin Oncol. 2010 Apr 10; 28(11):1963 -72.
Revised Protocol No.: 01
Date: 11-Sep-2017 77
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
9.1.4 Results of Central Radiology Assessments
The clinical management of participant s during the study  protocol  and secondary outcom es 
(PFS) will be based upon local radiologic tumor measurements and the invest igator -assessed 
RANO response criteria described in Secti on 9.1.3 . Radio logic imaging from this study  will be 
also be transmitted to a centralized imaging core lab for storage and for analysis by blinded 
independent central  review as determined by the Sponsor. The site will be informed of quality 
issues or need for repeat scanning via queries fro m the core lab.
9.2 Adverse Events
The definit ions of an AE or SAE can be found in Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally  authori zed representative). 
The invest igator and any designees are responsible for detecting, docum enting, and reporting 
events that meet the definit ion of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatm ent or the study , or that caused the 
participant to di scont inue before complet ing the study. 
Immune-mediated adverse events are AEs consistent with an immune -mediated mechanism or 
immune -mediated componen t for which non-inflammatory  etiologies (eg, infect ion or tumor 
progression) have been ruled out. IMAEs can include events with an alternate etiology which 
were exacerbated by the induct ion of autoimmunit y. Information supporting the assessment will 
be co llected on the participant’s case report form.
Contacts for SAE reporting specified in Appendix 3
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
The collect ion of nonseri ous AE information shoul d begin at initiation of study treatment until 
[the follow-up contact], at the timepo ints specified in the Schedule of Activities (Sect ion 2). 
Nonserious AE informat ion shoul d also be collected from the start of  a placebo lead-in peri od or 
other observational period intended to establish a baseline status for the participant s.
Secti ons 5.6.1 and 5.6.2 in the IBrepresent the Reference Safet y Inform ation to determine 
expectedness of serious adverse events for expedi ted reporting.47Following the participant’s 
written consent (or the parent/guardian/LAR’s permissi on) to participate in the study , all SAEs, 
whether related or not related to study drug, must be collected, including those thought to be 
associ ated wi th protocol -specified procedures.
All SAEs must be collected that occur during the screening period and within 100days of last 
dose of study treatm ent.For participants who are assigned treatm ent but never treated, SAEs 
shoul d be collected for 30 day s from the date of treatm ent assignment.
Medical occurrences that begin before the start of study treatm ent but after obtaining 
inform ed consent will be recorded on the appropriate section o f the eCRF section.
Revised Protocol No.: 01
Date: 11-Sep-2017 78
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
All SAEs will be recorded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3.
The invest igator will submi t any updated SAE data to the sponsor within 24 hours of this 
being available.
Invest igators are not obligated to actively seek AEs or SAEs in former study  participants. 
However, if the invest igator learns of any SAE, including a death, at any time after a participant 
has been disch arged from the study , and he/she considers the event reasonably related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify the sponsor.
The method of evaluat ing, and assessing causality  of AEs and SAEs and the procedures for 
completing and reporting/ transmi tting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited during open -ended quest ioning, 
examinat ion, or evaluation of a participant .Care shou ld be taken not to introduce bias when 
collect ing AEs or/or SAEs. Inquiry about specific AEs shoul d be guided by clinical judgment in 
the context of known adverse reactions, when appropriate for the next program or protocol. 
9.2.3 Follow -up of AEs and SAEs
Nons erious AEs shoul d be followed to resol ution or stabilizat ion, or reported as SAEs if they 
beco me serious (see Appendix 3).
Follow-up is also requi red for nonserious AEs that cause interruption or discont inuation of 
study  treatm ent and for those present at the end of study  treatm ent as appropri ate.
 All ident ified nonserious AEs must be recorded and described on the nonseri ous AE page of 
the CRF (paper or electronic). Com pletion of supplemental  CRFs may be requested for AEs 
and/or laboratory  abnorm alities that are reported/ident ified during the course of the study .
After the init ial AE/SAE report, the invest igator is required to proactively fo llow each parti cipant 
at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest (as defined in
Secti on 9.2will be followed until resolution, until the condi tion stabilizes, until the event is 
otherwi se explained, or until the participant is lost to fo llow-up (as defined in Section 8.3).
Further informat ion on fo llow-up procedures i s given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the inves tigator to the Sponsor of SAEs is essent ial so that legal 
obligat ions and ethical responsibilit ies towards the safet y of participants and the safet y of a 
product under clinical investigation are met.
An invest igator who receives an invest igator safety report describing SAEs or other specific 
safet y information (eg, summary  or listing of SAEs) from the Sponsor will file it along with 
the Invest igator’s Brochure and will notify  the IRB/IEC, if appropri ate according to local 
requi rements.
Revised Protocol No.: 01
Date: 11-Sep-2017 79
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Sponsor or designee will be reporting adverse events to regulatory  authori ties and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and 
FDA Code of Federal  Regulat ions 21 CFR Parts 312 and 320. A SUSAR (Suspected, 
Unexpected Serious Adverse React ion) is a subset of SAEs and will be reported to the 
appropriate regul atory  authori ties and invest igators following local and global guidelines and 
requi rements.
All SAEs must be collected that occur during the screening period and within 100days of the 
last dose of  study  treatm ent. For parti cipants randomized/assigned to treatm ent and never treated 
with study  drug, SAEs shoul d be co llected for 30 days from the date of treatm ent assignment.
9.2.5 Pregnancy
If, following initiation of the study  treatment, it is subsequent ly discovered that a participant is 
pregnant or may have been pregnant at the time of study exposure, including during at least 
5half-lives after product administration, the investigator must immediately notify the BMS 
Medical Moni tor/desi gnee of this event and complete and forward a Pregnancy Surveillance 
Form  to BMS Designee within 24 hours of awareness of the event and in accordance with SAE 
reporting procedures described in Appendix 3.
In most cases, the study  treatm entwill be perm anent ly discont inued in an appropri ate manner 
(eg,dose taperi ng if necessary  for participant safet y). Please call the BMS Medical Moni tor 
within 24 hours of aw areness of the pregnancy.
Follow-up informat ion regarding the course of the pregnancy, including perinatal  and neonatal 
outcom e and, where applicable, offspring informat ion must be reported on the Pregnancy 
Surveillance Form.
Any pregnancy that occurs in a female partner of a male study  participant should be reported to 
Sponsor or designee . In order for Sponsor or designee to collect any pregnancy surveillance 
inform ation from the female partner, the female partner must sign aninformed consent form for 
disclosure of this informat ion. Inform ation on this pregnancy will be collected on the Pregnancy 
Surveillance Form if permissible by local regulat ions.
9.2.6 Laboratory Test Result Abnormalities
The following laboratory  test resul t abn ormalities shoul d be captured on the nonseri ous AE CRF 
page or SAE Report Form  electronic ,as appropri ate. Paper f orms are only intended as a back-up 
option when the el ectronic system is not functioning.
Any laboratory  test resul t that is clinically signif icant or m eets the definit ion of an SAE 
Any laboratory  test resul t abnormalit y that required the participant to have study  treatm ent
discontinued or interrupted
Any laboratory  test resul t abnormalit y that required the participant to receive specific 
corre ctive therapy
Revised Protocol No.: 01
Date: 11-Sep-2017 80
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
It is expected that wherever possible, the clinical rather than laboratory  term would be used by 
the reporting invest igator ( eg, anemia versus low hemoglobin value).
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confi rmation of initial liver-related laboratory  abnormalit ies shoul d 
occur prior to the reporting of a  p otenti al DILI event. All occurrences of potenti al DILIs, 
meet ing the defined criteria, must be reported as SAEs (see Section 9.2and Appendix 3for 
reporting details). For the purposes of this trial, a fixed ULN = 45 will be used for AST and 
ALT. 
Potenti al drug induced liver injury  is defined as: 
1)AT (ALT or AST) elevation > 3 xULN , AND
2)Total  bilirubin > 2 xULN, without initial findings of cholestasis (elevated serum  alkaline 
phosphatase), AND
3)No other immediately apparent possible causes of AT elevat ion and hyperbilirubinemia, 
including, but not limited to, viral hepat itis, pre-exist ing chroni c or acute liver disease, or 
the administration o f other drug(s) known to be hepatotoxic.
9.2.8 Other Safety Considerations
Any significant worsening noted durin g interim or final physical  examinat ions, 
electrocardi ogram , x-ray filming, any other potential safet y assessment required or not required 
by protocol  should also be recorded as a nonserious or serious AE, as appropriate, and reported 
accordingly.
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 81
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
9.3 Overdose
An overdose is defined as the accidental  or intentio nal administrati on of any dose of a product 
that is considered both excessive and medically important. All occurrences of overdose must be 
reported as an SAE (see Section 9.2).
In the event of an overdose the [invest igator/tre ating physician] should:
1)Contact the Medical Monitor immediately
2)Closely  monitor the parti cipant for AEs/SAEs and laboratory  abnorm alities.
3)Docum ent the quantit y of the excess dose as well as the durati on of the overdosing in the 
CRF.
Decisio ns regarding dose interruptions or modificat ions will be made by the invest igator in 
consultation wit h the Medical Monitor based on the clinical evaluat ion of the participant.
9.4 Safety
Planned timepo ints for all safet y assessments are listed in the Schedule of Activit ies(Secti on 2).
Safety assessments include AEs, physical examinat ions, vital signs, performance status, 
assessment of signs and symptom s,laboratory  tests, and pregnancy tests as outlined in the 
Schedule of Act ivities.
Addit ional measures, including non-study  required laboratory  tests, shoul d be performed as 
clinically indicated or to com ply with local regulati ons. Laboratory  toxicities (eg , suspected drug 
induced liver enzyme evaluat ions) will be monitored during the follow-up phase via on si te/local 
labs unt il all study drug related toxicit ies reso lve, return to baseline, or are deemed irreversible.
If a participant shows pulm onary-related signs (hypoxia, fever) or symptoms (eg, dyspnea, 
cough, fever) consistent with possible pulmo nary adverse events, the participant should be 
immediately evaluated to rule out pulmo nary toxicit y, according to the suspected pulmo nary 
toxicity management al gorithm Appendix 5 .47
Some of the assessments referred to in this section may not be captured as data in the eCRF. 
They  are intended to be used as safet y monitoring by the treating physician. Addit ional testing or 
assessments may be perform ed as clinically  necessary  or wh ere required by institutional or local 
regul ations.
9.4.1 Physical Examinations
Refer to Schedule of Activitiesin Sect ion 2.
In addition to the usual physical  examinat ion, aneuro logic exam  is performed routi nely in a 
pediatric neuro -oncol ogy clinic. Neurol ogical exams are expected during Screening and at 
C1D1, and as clinically indicated. Normal institutional pract ice is expected. The exam includes 
observat ion of gait and coordinat ion, cranial nerve function (including speech and visual fields), 
extre mity strength and report of  bladder/bowel function, with particular attenti on to any changes 
in previously -noted deficits.
Revised Protocol No.: 01
Date: 11-Sep-2017 82
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
9.4.2 Vital signs
Refer to Sch edule of Activities in Sect ion 2.
9.4.3 Electrocardiograms
Refer to Schedule of Act ivities, Table 2. -3, fo r electrocardi ograms for Modul e B.A 12 -lead ECG 
shoul dbe perform ed during the study  period only  as clinically indicated .
9.4.4 Clinical Safety Laboratory Assessments
Invest igators must document their review of each laboratory  safety  report.
See Secti on 2 for addi tional details on the assessments to be conducted.
Laboratory  tests eval uated are incl uded in Table 9.4.4 -1.
Table 9.4.4 -1: Laboratory Tests
Hematology
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Serum Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Total bilirubin
Creatinine
Blood Urea Nitrogen (BUN)
Uric acid
Glucose
Total Protein -screening only
Albumin -screening onlySodium
Potassium
Chloride
Calcium -screening only
Phospho rus-screening only
Lipase (Module B only)
Amylase (Module B only)
Serology (screening only)
Serum for hepatitis C antibody, hepatitis B surface antigen, (HIV-1 and -2 antibody where mandated locally)
Other Analyses
TSH (reflex to free T3 and Free T4 only if abnormal)
Pregnancy test (WOCBP only: predose, discharge).
9.4.5 Imaging Safety Assessment
Any incidental findings of potenti al clinical relevance that are not direct ly associated with the 
objectives of the protocol  should be evaluated and handled by the Study  Investigator as per 
standard m edical/clinical judgment. 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 83
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 84
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
 
 
 
 
 
9.9 Health Economics OR Medical Resource Utilization and Health 
Economics
Health Economics/Medical Resource Utilizat ion and Health Economics param eters will not be 
evaluated in this study .
10. STATISTICAL CONSIDER ATIONS
10.1 Sample Size Determination
 
  
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 94
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
By applying the above methodology , the intended target number of parti cipants (N)for cohort 1 -
4 are obtained as fo llows:
Cohort 1:22participants are required (17 events) for each cohort. This assumes 80% power 
with a one sided Type 1 error of  10%, a histori cal median OS of 9 months (  
 ), 1-year accrual, 2 -year follow-up, and a target effect size o f median OS 15 m onths. 
Cohort 2:15participant s are requiredfor each cohort. This assumes 80% power with a 
one-sided Type 1 error of 10%, a historical PFS(6) of 18%  ), one -year accrual, 
one-year follow-up, a target PFS(6) of 38%. An interim analysis based on PFS(6) for futilit y 
only will be conducted after at least 8of the planned number of participant s are enrolled with 6 
months follow-up. In addition, all other available efficacy data will be evaluated in the futility 
analysis . The method is adapted according to Details of the futility criteria and 
simulat ions will be contained in the Statist ical Analysis Plan (SAP).
Cohort 3:15 participant s are required for each cohort. Thisassumes 80% power with a 
one-sided Type 1 error of  10%, 1-year accrual and 1-year follow-up, a historical median PFS(4) 
of 18%and a target PFS(4) of 38%(see  , equivalent to PFS(6) of23%) . An 
interim analysis based on PFS( 6) for futility only will be conducted after at l east 8 of the planned 
number of participant s are enrolled with 6months follow-up. In addit ion all other available 
efficacy  data will  be eval uated in the fut ility analysis.
Cohort 4:10 participant s are required for each cohort. This assumes at least 80% power with a 
one-sided Type 1 error of 10%, a histori cal median PFS of 2.1 months (see etopos ide arm of 
 ), 1-year accrual, 1-year follow-up, and a target median PFS of 4.4 m onths.
Cohort 5:18participants are required for each cohort. Sample sizes each of the expansio n 
Cohorts A5 and B5 is not based on statistical consi derati ons as these cohorts contain various 
tumor types. However, if the disease control  rate at 12 months is 30%, 18 participant s provide 
21% precision for the estimate.
Revised Protocol No.: 01
Date: 11-Sep-2017 95
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
10.2 Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
EnrolledAll participants who sign inform ed consent . This is the dataset 
for disposi tion.
TreatedAll enrolled participant s who received at least one dose of study 
drug. This is the dataset for safet y evaluat ion.
Safety Lead -in part icipantsIn Modul e A, the first 6 DLT -evaluable participants in Cohort 1 
and the first 10 DLT -evalu able participants in Cohorts 2-5; in 
Module B, the first 10 DLT -evaluable participants.
Response -evaluable 
participant sAll treated participant s with measurable disease at a baseline 
tumor assessment (Source: CRF).
 
  
        
 
 
10.3 Statistical Analyses
The statistical analysis plan will be devel oped and finalized before database lock and will 
describe the selection of participants to be included in the analyses, and procedures for 
accounting for missing, unused, and spuri ous data. Below is a summary of planned statistical 
analyses o f the primary  and secondary  endpoints.
10.3.1 Efficacy Analyses
The primary  efficacy  analyses will be perform ed on treated populat ion for the final analysis. 
Details on censoring scheme on time-to-event endpo ints such as OS, PFS, and DOR will be 
described in the SAP.Efficacy analysis will be perform ed by each cohort separately; however, 
treated participant s in the safety lead-in period who meet the inclusio n criteria for the 
corresponding cohort will also be included in the cohort analysis.
OS is defined as the time between the date of diagnosis and the date of death in Cohort 1 and the 
time between date of first dose and the date of death for Cohorts 2-5. A participant who has not 
died will be censored at the last known alive date. OS will be followed continuously while 
Revised Protocol No.: 01
Date: 11-Sep-2017 96
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
participant s are on study  drug and every 3 months via in-person or phone contact during the 
survival fo llow-up phase of the study  drug.
PFS is defined as the time from first dose to the date of the first documented tumor progression 
or death due to any cause. Parti cipant s who die without a repor ted prior progression will be 
considered to have progressed on the date of death. Participants who did not have disease 
progression or die will be censored at the date of last evaluable tumor assessment. Participant s 
who did not have any on study  tumor assessment and did not die will be censored at the first 
dose date. PFS will be determined by invest igators based on RANO criteria. First tumor 
assessments will occur at week 6 and 12, and will be at every  8 weeks for the first year and then 
every 12 weeks thereafter until disease progression is documented.
ORR is defined as the number of participant s whose BOR is confirmed CR or PR  divided by all 
participant swho are evaluable for response, ie have measurable disease at baseline. BOR is 
defined as the best response designat ion, as determined by invest igators, recorded between the 
date of first dose and the date of object ively documented progression per RANO criteria or the 
date of subsequent therapy , whichever occurs first. All available response designati ons will 
contribute to the BOR assessment. For participant s without documented progression or 
subsequent therapy , all available response designatio ns will contribute to the BOR assessments.
DOR for a participant with a BOR of CR or PR, is defined as the time between the date of first 
response and the date of the first obj ectively documented tum or progressi on per RANO or death, 
whichever occurs first.
Endpoint Statistical Analysis Methods
Primary
Cohort A1 and B1: OS For each cohort separately, OS curve will be estimated using the Kaplan -
Meier (KM) method. The distribution of OS in all treated participants 
will be compared against the historical control of an exponential 
distribution with median OS 9 mont hs (Cohen, Heideman ,et al) using a 
one-sided one-samplelog rank test when approximately 17 events have 
occurred or after each participant has been followed for at least 24 
months. Median OS and the corresponding two-sided 80% confidence 
intervals using the log -log transformation will be computed.
Cohort A2 and B2: PFS For each cohort separately, PFS curve will be estimated using the 
Kaplan -Meier (KM) method. The distribution of PFS in all treated 
participants will be compared against the historical control of an 
exponential distribution with media n PFS 2.25 months (Hwang, et al) 
using a one-sided one-sample log rank test when each participant has 
been followed for at least 12 months. Median PFS and the corresponding 
two-sided 80% confidence intervals using the log-log transformation 
will be computed.
Cohort A3 and B3: PFS For each cohort separately , PFS curve will be estimated using the 
Kaplan -Meier (KM) method. The distribution of PFS in all treated 
Revised Protocol No.: 01
Date: 11-Sep-2017 97
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Endpoint Statistical Analysis Methods
participant s will be compared against the historical control of an 
exponential distribution with PFS(4) equal to .18 using a one-sided one-
sample log rank test when either 15 events have occurred or each 
participant has been followed for at least 12 mont hs.Median PFS and 
the corresponding two-sided 80% confidence intervals using the log-log 
transformation will be computed.
Cohort A4 and B4: PFS For each cohort separately the distribution of PFS in all treated 
participant s will be compared against the historical control of an 
exponential distribution with media n PFS equal to 2.1 months using a 
one-sided one-sample log rank test when either 10 events have occurred 
or each p articipant has been followed for at least 12 months.
Cohort A5 and B5: PFS For each cohort separately individual PFS will be listed by tumor type 
after each participant reaches 12 mont hs follow -up. PFS curve will be 
estimated using the Kaplan -Meier (KM) method for all tumor types 
(pooled) and selected individual tumor types, if there is enough data.
Secondary
Cohort A1 and B1:
PFS, OS(12)Cohorts A1and B1: 
PFS isestimated by Kaplan -Meier method and the corresponding 95% 
CI for median OSwill be calculated via Brookmeyer and Crowley 
methodology using log-log transformation . OS(12) will be estimated 
using the Kaplan -Meier (KM) method. The corresponding 95% 
confiden ce interval for median OS will be calculated via Brookmeyer 
and Crowley methodology using log-log transformation and 
corresponding 95% confidence interval for OS(12) will be derived based 
on Greenwood form ula.All secondary endpoints will be analyzed at the 
time of the primary analysis.
Cohort A2 and B2:
PFS(6) , OS, OS(12)
Cohort A3 and B3:
PFS( 6), OS, OS(12)
Cohort A4 and B4:
PFS(6), OS, OS(12)Cohorts A 2, A3, A4, B 2, B3, B4
Secondary statistics analysis for other cohorts A2, A3, and A4, B2, B3, 
and B4 is the same as for Cohort A 1and B 1(except timepoint for OS(r) 
and PFS(r) may differ.
Cohort A5 and B5:
PFS(12), OSCohorts A5, B5:
OS will be listed.  OS curve will be computed using Kaplan -Meier 
method for pooled indications and selected individual indications. The 
corresponding 95% confidence interval for median OS will be calculated 
via Brookmeyer and Crowley methodology using log -log transformation 
and corresponding 95% confidence interval for PFS(12) will be derived 
Revised Protocol No.: 01
Date: 11-Sep-2017 98
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Endpoint Statistical Analysis Methods
based on Greenwood formula.
 
 
 
 
 
 
 
 
 
 
 
10.3.2 Safety Analyses
All safet y analyses will be performed on the treated population .
Endpoint Statistical Analysis Methods
Primary
Module A and B Safety 
Lead -in:
Incidence of AEs, SAEs, 
drug-related AEs, AEs 
leading to discontinuation, 
and death.
AEs will be g raded 
according to CTCAE v4.03.
Incidence of laboratory 
abnor malities
Laboratory values will be 
graded according to 
CTCAE v4.03.Module A and B Safety Lead -in:
Frequency distribution of treated participants with AE using the worst 
CTC grade. Participants will only be counted (1) once at the preferred 
term (PT) level, (2) once at the system organ class (SOC) level, and (3) 
once in the ‘Total participant ’ row attheir worst CTC grade, regardless 
of SOC or PT. By Cohort.
Lab shift table using the worst CTC grade per participant by Cohort.
Revised Protocol No.: 01
Date: 11-Sep-2017 99
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Endpoint Statistical Analysis Methods
Secondary
All Cohorts A1-A 5, B1-
B5:
Incidence of AEs, SAEs, 
drug-related AEs, AEs 
leading to discontinuation, 
and death.
AEs will be g raded 
according to CTCAE v4.03.
Incidence of laboratory 
abnor malities
Laboratory values will be 
graded according to 
CTCAE v4.03.All Cohorts A1-A 5, B1-B5:
Frequency distribution of treated participants with AE using the worst 
CTC grade. Parti cipants will only be counted (1) once at the preferred 
term (PT) level, (2) once at the system organ class (SOC) level, and (3) 
once in the ‘Total participant ’ row at their worst CTC grade, regardless 
of SOC or PT. By Cohort.
Lab shift table using the worst CTC grade per participant by Cohort.
 
 
 
 
 
 
 
 
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 100
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
10.3.5 Interim Analyses 
Cohorts A1 and B1:No interim analysis for futilityis planned, as the Cohorts are expected to 
be fully enrolled when the OS endpoint becomes available . However, in Modul e A if other 
indicat ions are stopped for futilit y,enrollment in Modul e B may be init iated based on 
recommendat ions of the Steering Co mmittee .
Cohorts A2 and B2: The interim futilit y analysis for Cohorts A2 and B2 (HGG) will be 
conducted using PFS(6) and after at least 8 participants have been followed for 6 months. In 
addition,all other available efficacy data will be evaluated in the fut ility analysis.
Cohorts A3 and B3: An interim analysis based on PFS(6) for futility only will be conducted 
after at least 8 of the planned number of participant s are enrolled with 6months follow-up. In 
addition all other available efficacy  data will  be eval uated in the fut ility analysis.
Cohorts A4 and B4:No interim analysis for futility is planned as the sam ple size i s too sm all.
Cohorts A5 and B5: No interim analysis for futilit yis planned as it is comprised of many 
diverse histo logies. However, in Modul e A if other indicat ions are stopped for fut ility enrollment 
in Modul e B m ay be init iated based on the recommendat ion of the Steering Co mmit tee.
For Cohorts 2 and 3: the Bayesian statistical methodol ogy is described in Bayesian Adaptive 
Methods for Clinical Trial by Berry  et al published in Chapman and Hall (2011) and is outlined 
here with adaptati ons from Lee and Liu A predict ive probabilit y design for phase II cancer 
clinical trials.
Cohort 4 has a smaller sample size than the other cohorts (n=10) so it is not appropriate to add an 
interim analysis for futility. For Cohorts 2 and 3:The Bayesian statistical methodol ogy is 
described in Bayesian Adaptive Methods for Clinical Trial by Berry  et al published in Chapman 
and Hall (2011) and is outlined here with adaptati ons from  Lee and Liu REF A predictive 
probabilit y desi gn for phase II cancer clinical trials. Clinical Trials. 2008 5(2):93 -106. 
1)Once 8 subjects have been followed for at least 6 months a Cox proporti onal hazards model 
will be fit to interim data and est imate of hazard rate ob tained.
2)Based on memoryless property  of exponent ial survival  times will be generated for each 
subject conditional on the observed data using the estimated hazard rate and one-sample log 
rank test applied to the fully enrolled cohort. The simulated trial will be declared success if 
log rank is significant.
3)Simulations will be repeated 1000 times. The predi ctive probabilit y of success is defined as 
the proporti on of  simulated tri als that are declared success based on observed interim data.
4)If predict ive probabilit y of success is <20%, fut ility may be declared. The totalit y of data will 
be considered in any decisio n to stop the cohort.
Detailed simulat ions will bedescribed in the Statistical Analysis Plan.
Revised Protocol No.: 01
Date: 11-Sep-2017 101
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
12. APPENDICES
Revised Protocol No.: 01
Date: 11-Sep-2017 108
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
APPENDIX 1 ABBREVIATIONS AND TR ADEMARKS
Term Definition
AA anaplast ic astrocy toma
ADA anti-drug ant ibodies
AE adverse event
AIDS acqui red immunodeficiency syndrome
ALT alanine aminotransferase
AST aspartate aminotransferase
AT/RT atypical teratoi d/rhabdo id tumor
AUC area under the concentration -time curve
BICR blinded independent central review committee
BMS Bristol-Myers Squibb
BOR best overall response
BP blood pressure
BUN blood urea nitrogen
C Celsius
CBC complete bl ood count
CFR Code of Federal Regulat ions 
cHL classic Hodgkins lympho ma
CI confidence interval
C1- chloride
CLcr creatinine clearance
cm centimeter
Cmax, CMAX maximum observed concentration
CNS Central  nervous system
CR complete response
CRC colorectal  cancer
CRF Case Report Form, paper or electronic
CSF cerebrospinal fluid
CV coefficient of variat ion
DILI Drug induced liver injury
Revised Protocol No.: 01
Date: 11-Sep-2017 109
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Term Definition
DIPG diffuse intrinsic pontine glioma
dL deciliter
DLT dose limit ing toxicit y
DMC Data m onitoring committee
DNA deoxy ribonucleaic acid
DOR durati on of  response
ECG electrocardi ogram
eCRF electronic Case Report Form
EFS event free survival
eg exempli gratia (for example)
EOI end of infusio n
EOMES eomesodermin
ESR Expedited Safet y Report
ETMR embry onal tumor wi th multilayered rosettes
FDA Food and Drug Administration
FFPE formalin-fixed paraffin -embedded
FLAIR fast fluid -attenuated inversio n recovery
FSH follicle stimulat ing horm one
GBM glioblastoma
GCP Good Clinical Pract ice
GFR glomerular filtrat ion rate
HBsAg hepat itis B surface antigen
HBV hepat itis B virus
HCC hepatocell ular carcino ma
HCG human chorionic gonadotropin
HCV hepat itis C virus
HCV -RNA hepat itis C virus -ribonucleic acid
HGG high grade glio ma
HIV Hum an Immunodeficiency Virus
HLA human leukocy te anti gen
Revised Protocol No.: 01
Date: 11-Sep-2017 110
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Term Definition
HR heart rate ; hazard ratio
IB Invest igator Brochure
ICD implantable cardioverter defibrillator
ICF inform ed consent form
ICH International Conference on Harm onisati on 
ICOS inducible T cell co -stimulator
ie id est (that is)
IEC Independent Ethics Committee
IHC immunohistochemistry
IMAE Immune-mediated adverse event
IMG immunogenicit y
IMP investigat ional medicinal products
IND Invest igational New Drug Exem ption
IP investigat ional product
ir immune -related
IRB Institutional Review Board
IRT Interactive Response Techno logy
IU International Unit
IV intravenous
K+ potassi um
KPS Karno fsky Performance Score
kg kilogram
L liter
LAM Lactati on amenorrhea m ethod
LDH lactate dehy drogenase
LFT(s) liver funct ion test (s)
LPS Lansky P layScore
mg milligram
MGMT O6-methylguanylmethyltransferase
min minute
Revised Protocol No.: 01
Date: 11-Sep-2017 111
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Term Definition
mL milliliter
MLR mixed lymphocy te reacti on
MRI magnet ic resonance imaging
MS mass spectrom etry
MTD maximum tolerated dose
g microgram
N number of subjects or observations
N Nivo lumab (BMS -936558)
Na+ sodium
NE not evaluable
NSCLC non-small  cell lung carcino ma
OR objective response
ORR objective response rate
OS overall survival
PBMC peripheral  blood m ononuclear cell
PD progressive disease 
PD pharmacodynamics
PD-1 Programmed cell death protein 1
PD-L1 Programmed cell death ligand 1
PFS progression free survival
PK pharmacokinet ics
PO per os (by mouth route of administration)
PR partial response
QC qualit y control
QD, qd quaque di e, once daily
R2coefficient of determinat ion
RANO Radiologic Assessment in Neuro -Onco logy
RBC red bl ood cell
RCC Renal cell carcino ma
RT radiotherapy
Revised Protocol No.: 01
Date: 11-Sep-2017 112
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Term Definition
SAE serious adverse event
SCLC squamous cell lung carcino ma
SD standard deviat ion; stable disease
SmPC Summary  of Product Characteristics
SOP Standard Operating Procedures
SSC study  steering committee
t temperature
T time
TAO Trial Access Online, the BMS implementation of an EDC capabilit y
TCR T cell receptor
TILs Tumor infiltrating lymphocy tes
WBC white blood cell
WHO World Heal th Organizat ion
WOCBP wom en of childbearing potential
Revised Protocol No.: 01
Date: 11-Sep-2017 113
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
APPENDIX 2 STUDY GOVER NANCE CONSIDERATIONS
The term  ‘Parti cipant’ i s used in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term ‘Subject’ used in the eCRF is intended to refer to a person 
(Parti cipant) who has consented to participate in the clinical research study .
REGULATORY AND ETHIC AL CONSIDERATIONS
GOOD CLINICAL PRACTI CE
This study  will be conducted in accordance wit h:
Good Clinical Pract ice (GCP), 
as defined by  the Internat ional Council on Harmo nisati on (ICH)
in accordance wit h the eth ical principles underlying Euro pean Unio n Directive 2001/20/EC
United States Code of Federal Regulations, Tit le 21, Part 50 (21CFR50) 
Consensus ethical principles derived from internatio nal guidelines including the Declarat ion 
of Helsinki and Council for Internat ional Organizat ions of Medical Sciences (CIOMS) 
International Ethical Guidelines
applicable local requirements.
The study  will be conducted in com pliance wi th the protocol . The protocol  and any amendments 
and the participant informed consent will receive approval/favorable opinio n by Institutional 
Review Board/Independent Ethics Committee (IRB/IEC) , and regul atory  authori ties according to 
applicable local regulat ionsprior to init iation of the study .
All potenti al serious breaches must be reported to Sponsor or designee immediately. A serious
breach is a breach of the conditions and principles of GCP in connect ion with the study  or the 
protocol , which is likely to affect, to a significant degree, the safet y or physical or mental integrit y 
of the sub jects of the study  or the sci entific value of the study.
Personnel involved in conducting this study  will be qualified by educat ion, training, and 
experience to perform their respective tasks.
This study  will not use the services of study personnel where sancti ons have been invoked or where 
there has been scient ific misconduct or fraud ( eg, loss of medical licensure, debarment). 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ET HICS COMMITTEE
Before study  initiation, the invest igator must have written and dated approval/favorable opinio n 
from the IRB/IEC for the protocol , consent form, participant recruitment materials 
(eg,advertisements), and any other written information to be provided to subjects. The investigator 
or BMS shoul d also provi de the IRB/IEC with a copy of the Invest igator Brochure or product 
labeling informat ion to be provided to subjects and any updates. 
The invest igator, Sponsor or designee should provide the IRB/IEC with repo rts, u pdates and other 
inform ation (eg, expedited safet y reports, amendments, and administrative letters) according to 
regul atory  requi rements or i nstitution procedures.
Revised Protocol No.: 01
Date: 11-Sep-2017 114
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
COMPLIANCE WITH THE PROTOCOL AND PROTOCO L REVISIONS
The invest igator should not implement any deviati on or change to the protocol  without prior 
review and docum ented approval /favorabl e opini on of an amendment from the IRB/IEC (and if 
applicable, also by local health authori ty)except where necessary to eliminate an immediate 
hazard(s) to study  subjects. 
If a deviat ion or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opinio n(s) the deviat ion or change will be submi tted, as 
soon as poss ible to:
IRB/IEC for 
Regulatory  Authori ty(ies), if applicable by  local regul ations (per nat ional requirements)
Docum entati on of approval /favorabl e opinio n signed by the chairperson or designee of the 
IRB(s)/IEC(s) and if applicable, also by local healt h authori ty must be sent to BMS.
If an amendment substant ially alters the study  design or increases the potential risk to the 
participant : (1) the consent form must be revised and submi tted to th e IRB(s)/IEC(s) for review 
and approval/favorable opinio n; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study  if they are affected by the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revisio n is done via an a dministrati ve letter, investi gators m ust inform  their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Invest igators and sub-Invest igators will provi de the Sponsor with sufficient, accurate financia l 
inform ation in accordance with local regulati ons to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statem ents to the appropriate healt h authori ties. 
Invest igators are responsible for provi ding information on financial interests during the course of 
the study  and f or 1 year after com pletion of the study .
INFORMED CONSENT PRO CESS
Invest igators must ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other crit ical issues regarding clinical studies in which they  volunteer to participate. 
In situat ions where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other 
critical issues regarding clinical studies in which the partic ipant volunteers to participate. 
Sponsor or designee will provi de the investigator with an appropriate (i.e., Global or Local) sample
inform ed consent form which will include all elem ents requi red by ICH, GCP and applicable
regul atory  requirements. The sample inform ed consent form will adhere to the ethical principles 
that have their origin in the Declaration o f Helsinki.
Revised Protocol No.: 01
Date: 11-Sep-2017 115
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Invest igators must:
Provi de a copy  of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study part icipation. The language must 
be non-technical and easily  understood. 
Allow time necessary for participant or participant 's legally acceptable representative to 
inquire about the details o f the study .
Obtain a n informed consent signed and personally dated by  the partici pant or the participant 's 
legally acceptable representative and by the person who conducted the informed consent 
discussio n. 
Obtain the IRB/IEC’s written approval/favorable opinio n of the written informed consent form 
and any other informat ion to be provided to the subjects, prior to the beginning of the study , 
and after any revisio ns are com pleted for new info rmation.
If inform ed consent is initially given by a partici pant’s legally acceptable representative or legal 
guardi an, and the participant subsequent ly beco mes capable of making and communicat ing his or 
her informed consent during the study, consent must additionally be obtained from the participant .
Revise the informed consent whenever important new informat ion beco mes available that is 
relevant to the participant 's consent. The invest igator, or a person designated by the invest igator, 
shoul d fully inform  the participant or the participant 's legally acceptable representative or legal 
guard ian, of all pertinent aspects of the study  and of any new information relevant to the 
participant 's willingness to conti nue participat ion in the study . This communication shoul d be 
docum ented. 
The confidentialit y of records that could ident ify subjects must be protected, respecting the privacy 
and confident iality rules applicable to regulatory  requi rements, the subjects' signed ICF and, in the 
US, the subjects’ signed HIPAA Authorizat ion.
The consent form must also include a statem ent that BMS and regul atory authori ties have direct 
access to participant records. 
For minors, according to local legislat ion, one or both parents or a legally acceptable representative 
must be informed of the study  procedures and m ust si gn the informed consent form  approved for 
the study  prior to clinical study  participat ion. The explicit wish of a minor, who is capable of 
forming an opinio n and assessing this informat ion to ref use participat ion in, or to be withdrawn 
from, the clinical study  at any  time shoul d be considered by the invest igator. 
Minors who are judged to be of an age of reason must also give their written assent.
Subjects unable to give their written consent ( eg, stroke or subjects with or severe dement ia) may 
only be enro lled in t he study with the consent of a legally acceptable representative. The partici pant
must also be informed about the nature of the study  to the extent compatible with his or her 
understanding, and shoul d this partici pant become capable, he or she shoul d personally  sign and 
date the consent form as soon as possible. The explicit wish of a participant who is unable to give 
his or her wri tten consent, but who is capable of forming an opinion and assessing information to 
Revised Protocol No.: 01
Date: 11-Sep-2017 116
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
refuse participat ion in, or to be withdrawn fro m, the clinical study at an y time should be considered 
by the investigator.
The ri ghts, safet y, and well -being of the study  subjects are the m ost important considerati ons and 
shoul d prevail  over interests of science and societ y.
SOURCE DOCUMENTS
The Investi gator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, ori ginal  and attributable, whether the data are hand -written on paper or entered 
electroni cally. If source data are created (first entered), modified, maintained, archived, retrieved, 
ortransmitted electroni cally via computerized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such system s must be compliant with all 
applicable laws and regulati ons governing use of electronic records and/or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/healt h records (EMRs/EHRs), 
adverse event tracking/reporting, protocol  required assessments, and/or drug accountabilit y 
records).
When paper records from such system s are used in place of electronic format to perform regulated 
activit ies, such paper records should be certified copies. A certified copy  consists of a copy of 
original  informat ion that has been verified, as indicated by a dated signature, as an exa ct copy 
having all o f the sam e attri butes and informat ion as the original. 
STUDY TREATMENT RECO RDS
Records for study treatm ents nivolumab and ipilimumab (whether supplied by BMS, i ts vendors, 
or the site) must substant iate study  treatmentintegrity and traceabilit y from receipt, preparation, 
administration, and through destruction or return. Records must be made available for review at 
the request of BMS/designee or a Health Authority.
Revised Protocol No.: 01
Date: 11-Sep-2017 117
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
If Then
Supplied by BMS (or its 
vendors):Records or logs must comply with applicable regulations and guidelines and should 
include:
amount received and placed in storage area
amount currently in storage area
label identification number or batch number
amount dispensed to and returned by each participant , including unique 
participant identifiers
amount transferred to another area/site for dispensing or storage
nonstudy  disposition (e.g., lost, wasted) 
amount destroyed at study site, if applicable
amount returned to BMS
retain samples for bioavailability/bioequivalence, if applicable 
dates and initials of person responsible for Investigational Product 
dispensing/accountability, as per the Delegation of Authority Form.
Sourced by site, and not 
supplied by BMS or its 
vendors (examples include 
IP sourced from the sites 
stock or commercial 
supply, or a specialty 
pharmacy)The investigator or designee accepts responsibility for documenting traceability and 
study drug integrity in accordance with requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.  
These records should include:
label identification number or batch number 
amount dispensed to and returned by each participant , including unique 
participant identifiers
dates and initials of person responsible for Investigational Product 
dispensing/accountability, as per the Delegation of Authority Form.
BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an 
established system that meets these requirements.
CASE REPORT FORMS
An investigator i s requi red to prepare and m aintain adequate and accurate case histories designed 
to record all observat ions and other data pertinent to the invest igation on each individual treated 
or entered as a control in the invest igation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Addit ional clinical informat ion may be collected and analyzed in an effort to enhance 
understanding o f product safet y. CRFs may be requested for AEs and/or laboratory  abnorm alities 
that are reported or ident ified during the course of the study .
For sites using the Sponsor or designee electronic data capture tool, electroni c CRFs will be 
prepared for all data collect ion field s except for fields specific to SAEs and pregnancy, which will 
be reported on the electroni c SAE form and Pregnancy Surveillance form, respect ively. If 
electroni c SAE form is not available, a paper SAE form can be used. Spaces may be left blank 
only in those circumstances permitted by study -specific CRF completion guidelines provi ded by 
Sponsor or designee. 
The confidentialit y of records that could ident ify subjects must be protected, respecting the privacy 
and confidentialit y rules in accordance wi th the applicable regulatory  requi rement(s).
Revised Protocol No.: 01
Date: 11-Sep-2017 118
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
The invest igator will maintain a signature sheet to document signatures and init ials of all persons 
authori zed to m ake entri es and/or corrections on CRFs. 
The co mpleted CRF, SAE/pregnancy CRFs, must be pro mptly review ed, signed, and dated by the 
investigator or qualified physician who is a subinvesti gator and who is delegated thi s task on the 
Delegati on of  Authori ty Form. Subinvest igators in Japan may not be delegated the CRF approval 
task.For electronic CRFs, review and approval/signature is completed electroni cally through the 
BMS electroni c data capture tool. The invest igator must retain a copy  of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electroni c CRFs must meet Sponsor or designee training 
requi rements and must only access the BMS electronic data capture tool using the unique user 
account provided by Sponsor or designee. User accounts are not to be shared or reassigned to other 
individuals
MONITORING
Sponsor or designee representatives will review data centrally to ident ify potenti al issues to 
determine a schedule of on -site visi ts for targeted review o f study  records. 
Representatives of BMS must be allowed to visit all study  site locati ons peri odically to as sess the 
data qualit y and study  integrity. On si te they  will review study  records and directly co mpare them 
with source docum ents, discuss the conduct of the study  with the invest igator, and verify that the 
facilit ies remain acceptable .Certain CRF pages and/or electronic files may serve as the source 
docum ents.
In addi tion, the study  may be evaluated by  Sponsor or desi gnee internal auditors and government 
inspectors who must be allowed access to CRFs, source documents, other study  files, and study 
facilit ies. BMS audit reports will be kept confidential.
The investigator must notify BMS prom ptly of any inspect ions scheduled by regulatory authori ties, 
and prompt ly forward copi es of  inspect ion reports to Sponsor or designee.
RECORDS RETENTION
The invest igator (or head of the study  site in Japan) must retain all study records and source 
docum ents for the maximum period requi redby applicable regulat ions and guidelines, or 
institution procedures, or for the period specified by BMS or designee, whichever is longer. The 
investigator (or head of the study site in Japan) must contact BMS prior to destroying any records 
associ ated wi th the study .
BMS or desi gnee will notify the invest igator (or head of the study  site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study  (eg, relocation, retirement), the records shall be 
transferred to a mutually  agreed upon desi gnee ( eg., another investigator, study site, IRB). Notice 
of such transfer will be given in writ ing to BMS or designee. 
Revised Protocol No.: 01
Date: 11-Sep-2017 119
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
RETURN OF STUDY TREA TMENT
For thi s study , study  treatm ents (those supplied by  BMS, a vendor or sourced by  the invest igator) 
such as partially  used study  treatm ent containers, vials and syringes may  be destroy ed on si te. 
If.. Then
Study treatments supplied by BMS 
(including its vendorsAny unused study treatments supplied by BMS can only be 
destroy ed after being inspected and reconciled by the responsible 
Study Monitor unless study treatments containers must be 
immediately destroyed as required for safety, or to meet local 
regulations ( eg, cy totoxics or biologics).
If study treatments will be returned, the return will be arranged by 
the responsible Study Monitor.
Study treatments sourced by site, not 
supplied by BMS (or its vendors) 
(examples include study treatments 
sourced from the sites stock or commercial 
supply, or a specialty pharmacy)It is the investigator ’s or designee’s responsibility to dispose of all 
containers according to the institutional guidelines and procedures.
It is the invest igator’s or designee’s responsibilit y to arrange for disposal, provided that procedures 
for proper disposal have been established according to applicable federal, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The fo llowing minimal standards must be met:
On-site disposal  pract ices must not expose huma ns to ri sks fro m the drug.
On-site disposal pract ices and procedures are in agreement with applicable laws and 
regul ations, including any special requirements for controlled or hazardous substances.
Written procedures for on-site disposal  are available andfollowed. The procedures must be 
filed with the site’s SOPs and a copy  provi ded to BMS upon request.
Records are maintained that allow for traceabilit y of each container, including the date 
disposed of, quanti ty disposed, and ident ification of the person disposing the containers. The 
method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor 
must be documented.
Accountabilit y and disposal  records are complete, up- to-date, and available for the Monitor to 
review throu ghout the clinical trial period.
It is the invest igator’s or designee’s responsibilit y to arrange for di sposal  of all empt y containers.
If condit ions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by BMS (or its vendors). Destruction of non-study 
treatm ents sourced by the site, not supplied by BMS, is solely the responsibilit y of the invest igator 
or desi gnee.
For this study , study  treatm ents (those supplied by BMS or its vendors )such as full or partially 
used study  treatm ent containers, vials, sy ringes cannot be destroy ed on -site.
Revised Protocol No.: 01
Date: 11-Sep-2017 120
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
It is however, the invest igator’s or designee’s responsibilit y to arrange for disposal of all empt y 
study  treatment containers, provided that procedures for proper disposal have been established 
according to applicable federal, state, local, and institutional guidelines and procedures, and 
provi ded that appropriate records of disposal are kept. The return of full or partially used study 
treatm ents supplie d by BMS or i ts vendors will be arranged by the responsible Study  Moni tor.
CLINICAL STUDY REPOR T AND PUBLICATIONS
A Signatory  Invest igator must be selected to sign the clinical study report. 
For this protocol, the Signatory Invest igator will be selected a s appropriate based on the fo llowing 
criteria:
External Principal Invest igator designated at protocol development
National Coordinating Invest igator 
Study  Steering Committee chair or their designee
Parti cipant recruitment ( eg, among the top quartile of enrollers)
Involvement in trial design
Regional representati on (eg, among top quartile of enro llers fro m a specified region or country)
Other criteria (as determined by  the study  team )
The data collected during thi s study  are confident ial and propri etary  toSponsor or desi gnee. Any 
publicat ions or abstracts arising from this study  must adhere to the publicat ion requi rements set 
forth in the clinical trial agreement (CTA) governing [Study  site or Investi gator] participation in 
the study . These requi rements in clude, but are not limi ted to, submi tting proposed publicat ions to 
Sponsor or designee at the earliest practicable time prior to submissio n or presentation and 
otherwi se wi thin the time period set forth in the CTA.
Revised Protocol No.: 01
Date: 11-Sep-2017 121
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS : 
DEFINITIONS AND PROC EDURES FOR RECORDING , 
EVALUATING, FOLLOW U P AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) i s defined as any  new untoward m edical  occurrence or worsening of a 
preexist ing medical condit ion in a clinical invest igation participant administered study drug and 
that does not necessarily have a causal relat ionship wi th this treat ment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnorm al laboratory 
finding), symptom, or di sease tem porally associ ated wi th the use of  study  drug, whether or not 
considered related to the study  drug.
Revised Protocol No.: 01
Date: 11-Sep-2017 122
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
SERIOUS ADVERSE EVEN TS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which the participant was at ri sk of  death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were 
more severe)
Requi res inpat ient hospitalization or causes prolongation of exist ing hospi talizat ion (see NOTE 
below)
NOTE:
The fo llowing hospi talizati ons are not consi dered SAEs in BMS clinical studies: 
oa visit to the emergency  room  or other hospi tal departm ent < 24 hours, that does 
not result in admissio n (unless considered an important medical or 
life-threatening event)
oelective surgery, planned prior to signing consent
oadmissio ns as per protocol for a planned medical/surgical procedure
orouti ne health assessment requiring admissio n for baseline/trending of health 
status ( eg, routine colonoscopy )
omedical/surgical admissi on other than to rem edy ill healt h and planned prior to 
entry  into the study . Appropri ate documentati on is requi red in these cases
oadmissio n encountered for another life circumstance that carries no bearing on 
healt h status and requires no medical/surgical intervent ion (eg, lack of housing, 
economic inadequacy, caregiver respi te, family circumstances, administrative 
reason)
oadmissio n for administration of anticancer therapy in the absence of any other 
SAEs (applies to oncology  protocol s)
Results in persistent or significant di sabili ty/incapaci ty
Is a congenital ano maly/birth defect
is an important m edical event (defined as a medical event(s) that m ay not be immediately life-
threatening or resul t in death or hospi talizat ion but, based upon appropriate medical and 
scientific judgment, may jeopardi ze the participant or may require intervent ion [eg, medical, 
surgi cal] to prevent one of the other seri ous outcomes listed in the definit ion above.) Examples 
of such events include, but are not limited to, intensive treatm ent in an emergency  room or at 
home for allergic bronchospasm; blood dyscrasias or convulsio ns that do not resul t in 
hospi talizati on.) Potenti al drug induced liver injury  (DILI) is also considered an important 
medical event. (See Section 8.1.1 for the definit ion of potenti al DILI.) 
Revised Protocol No.: 01
Date: 11-Sep-2017 123
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Suspected transmissio n of an infectious agent (e.g., pathogenic or nonpathogenic) via the study 
treatm entis an SAE. 
Although pregnancy , overdose, cancer, and potent ial drug induced liver injury (DILI) are not 
always serious by regulatory  definit ion, these events must be handled as SAEs. (See Section 9.2.5
for reporting pregnancies).
Any co mponent of a study  endpoint that i s considered related to study  therapy  shoul d be reported 
as SAE (eg, death is an endpo int, if death occurred due to anaphylaxis, anaphylaxis must be 
reported).
EVALUATING AES AND S AES
Assessment of Causality
The causal relationship to study  drug is determined by  a physician and shoul d be used to assess 
all adverse events (AE). The causal relat ionship can be one of the fo llowing:
Related: There is a reasonable causal relat ionship between study  drug administration and 
the AE.
Not related: There is not a reasonable causal relationship between study  drug 
administration and the AE. 
The term "reasonable causal  relationship" means there is evidence to suggest a causal 
relationship. 
Follow -upof AEs and SAEs
If only limited informat ion is initially available, follow-up reports are requi red. (Note: Foll ow-
up SAE reports must include the same invest igator term(s) init ially reported.) 
If an ongoing SAE changes in its intensity or rel ationship to study drug or if new informat ion 
beco mes available, the SAE report m ust be updated and submi tted wi thin 24 hours to BMS (or 
designee) using the same procedure used for transmitting the init ial SAE report.
All SAEs must be fo llowed to resol ution or stabi lizati on.
Revised Protocol No.: 01
Date: 11-Sep-2017 124
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
REPORTING OF SAES TO SPONSOR OR DESIGNEE
SAEs, whether related or not related to study  drug, and pregnancies must be reported to BMS 
(or designee) within 24 hours of awareness of the event.
SAEs m ust be recorded on the SAE Report Form; pregnanc ies on a Pregnancy Surveillance 
Form (electronic or paper forms).
The preferred method for SAE data reporting collection is through the eCRF.
The paper SAE/pregnancy surveillance forms are only intended as a back-up option when 
the eCRF system is not funct ioning.
oIn this case, the paper forms are to be transmitted via email or confirmed 
facsimile (fax) transmissio n to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number: Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
requi red method for reporting. In the event the electronic system is unavailable for transmissio n, 
paper forms must be used and submitted immediately. When paper forms are used, the origin al 
paper form s are to rem ain on si te.
SAE Telephone Contact (required for SAE and pregnancy  reporti ng): Refer to Contact 
Inform ation list
Revised Protocol No.: 01
Date: 11-Sep-2017 125
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARIN G POTENTIAL DEFINITI ONS AND 
METHODS OF CONTRACEP TION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
perm anent ly sterile. Perm anent sterilizat ion methods include hysterectomy, bilateral 
salpingectomy , and bilateral  oophorectomy.
Women in the following categories are not considered WOCBP
Prem enarchal
Prem enopausal  female wi th 1 of the fo llowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
Note: Docum entati on can come from the site personnel’s review of the partici pant’s medica l 
records, medical examinat ion, or m edical history  interview.
Postmenopausal  female
A postm enopausal state i s defined as 12 m onths of am enorrhea in a wom an over age 45 y ears 
in the absence of other biological or phy siological causes. In addition, females under the age 
of 55 years must have a serum follicle stimulat ing horm one (FSH) level > 40 mIU/ml to 
confirm menopause. 
CONTRACEPTION GUIDAN CE FOR FEMALE PARTIC IPANTS OF CHILD BEAR ING 
POTENTIAL
One of the highly effective methods of contracepti on listed below is requi red during study 
durati on and unt il the end of relevant systemic exposure , defined as 5 months weeks after the end 
of study  treatm ent. 
Local  laws and regul ations may requi re use of alternative and/or addit ional contracepti on 
methods.
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year w hen used consistently and correctly.a
Combined (estrogen -and progestogen -containing) horm onal contracepti on associ ated with 
inhibit ion of ovulationb 
oral 
intravaginal 
transderm al 
Revised Protocol No.: 01
Date: 11-Sep-2017 126
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Progestogen -only hormonal contraception associated with inhibition of ovulationb 
oral 
injectable 
Highly Effective Methods That Are User Independent
Implantable progestogen -only hormonal contracepti on associated with inhibit ion of 
ovulation b
Horm onal methods of contracepti on including oral contraceptive pills containing a 
combinat ion of estrogen and progesterone, vaginal ring, injectables, implants and 
intrauterine hormone -releasing system  (IUS)c
Intrauterine device (IUD)c
Bilateral tubal occl usion
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
WOCBP participant s who choose complete abstinence must continue to have pregnancy 
tests, as specified in Section 2. 
Acceptable alternate methods of highly effective contraception must be discussed in the 
event that the WOCBP participants chooses to forego complete abst inence 
NOTES: 
aTypical use failure rates may  differ from those when used consistently  and correctly . Use should be consistent 
with local regulatio ns regarding the use of contraceptive methods for participants participating in clinical 
studies. 
bHormonal contraception may be susceptible to interactio n with the study drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence 
that the IMP and other study medications will not alter ho rmonal exposures such that contraception would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative 
methods of contraception should be utilized. 
cIntrauterine devices and intraut erine ho rmone releasing sy stems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter 
contraception effectiveness
Revised Protocol No.: 01
Date: 11-Sep-2017 127
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Unacceptable Methods of Contraception
Male or female condo m with or without spermicide.1, 2Male and female condoms cannot 
be used simultaneously
Diaphragm  with spermicide
Cervical cap wit h spermicide
Vaginal Sponge with spermicide
Progestogen -only oral hormonal contracepti on, where inhibit ion of ovulation is not the 
primary  mechanism o f action
Periodic abst inence (calendar, symptothermal, post -ovulation methods)
Withdrawal (co itus interruptus).
Spermicide only
Lactati on amenorrhea m ethod (LAM)
CONTRACEPTION GUIDAN CE FOR MALE PARTIC IPANTS WITH PARTNER( S) OF 
CHILD BEARING POTENT IAL.
Male participants with female partners of childbearing potenti al are eligible to participate if they 
agree to the fo llowing during the treatment and until the end of relevant sy stemic exposure.
Inform  any and all partner(s) of their participation in a clinical drug study  and the need to 
comply with contracepti on instructi ons as di rected by  the investi gator.
Male participants are requi red to use a condom for study  duration and until end of relevant 
systemic exposure defined as 7 months after the end of study  treatm ent.
Female partners of males participat ing in the study  to consider use of effective methods of 
contraception until the end of relevant systemic exposure, defined as 7 months after the end 
of treat ment in the male part icipant.
Male participants with a  pregnant or breastfeeding partner must agree to remain abstinent 
from penile vaginal intercourse or use a male condom  during each episode of penile 
penetrati on during the treatment and until 7 months after the end of study  treatm ent. 
Refrain from donating sperm  for th e duration of the study  treatment and until 7 months after 
the end of study  treatm ent.
COLLECTION OF PREGNA NCY INFORMATION
Guidance for collection of Pregnancy  Inform ation and outcom e of pregnancy on the Pregnancy 
Surveillance Form is provided in Sect ion 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definit ions and procedures for Evaluat ing, Fo llow-up and Reporti ng.
Revised Protocol No.: 01
Date: 11-Sep-2017 128
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
 
 
Revised Protocol No.: 01
Date: 11-Sep-2017 129
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
Revised Protocol No.: 01
Date: 11-Sep-2017 130
2.0
Approved
930109651
2.0
v

Clinical Protocol CA209908
BMS -936558 nivolumab
APPENDIX 6 KARNOFSKY AND LANSKY CRITERIA
STATUS STATUS
KARNOFSKY LANSKYKARNOFSKY or 
LANSKY
Normal, no complaints Fully  active, no rmal 100
Able to carry on normal activities; minor signs or 
symptoms of diseaseMinor restrictions in 
physically  strenuous 
activity90
Normal activity with effort; some signs or symptoms of 
diseaseActive, but tires more 
quickly80
Cares for self. Unable to carry on normal activity or to do 
active workSubstantial restriction of, 
and less time spent, in play 
activity70
Requires occasional assistance, but able to care for most of 
his needsOut of bed, but minimal 
active play; keeps busy 
with quiet activities60
Requires considerable assistance and frequent medical care Gets dressed, but inactive 
much of day; no active 
play, able to participate in 
quiet play50
Disabled. Requires special care and assistance Mostly in bed; participates 
in some quiet activities40
Severely  disabled. Hospitalization indicated though death 
non imminentIn bed; needs assistance 
even for quiet play30
Very  sick. Hospitalizatio n necessary . Active supportive 
treatment necessaryOften sleeping; play 
limited to passive 
activities20
Moribund No play; does not get out 
of bed10
Revised Protocol No.: 01
Date: 11-Sep-2017 138
2.0
Approved
930109651
2.0
v
